SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-1)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
SYMPHONIX DEVICES, INC.
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
871951 109
(CUSIP Number)
Hans Mehl
Siemens Audiologische Technik GmbH
Gebbertstrasse 125
D-91058 Erlangen
Federal Republic Of
Germany
011-49-9131-308-200
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
Copy to:
Kenneth R. Meyers, Esq.
Siemens Corporation
1301 Avenue of the Americas
New York, New York 10019
(212) 258-4000
December 1, 1999
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following
box. |_|
(Continued on following pages)
(Page 1 of 14 Pages)
<PAGE>
- --------------------------- -------------------------
CUSIP No. 13D Page 2 of 14
871951 109
- --------------------------- -------------------------
============ ===================================================================
1.
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY)
Siemens Audiologische Technik GmbH
===================================================================
============ ===================================================================
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)|_|
(b) X
===================================================================
============ ===================================================================
3.
SEC USE ONLY
===================================================================
============ ===================================================================
4.
SOURCE OF FUNDS
WC
===================================================================
============ ===================================================================
5.
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) OR 2(e)
|_|
===================================================================
============ ===================================================================
6.
CITIZENSHIP OR PLACE OF ORGANIZATION
Federal Republic of Germany
========================= ------- ==============================================
7. SOLE VOTING POWER
NUMBER OF
SHARES 1,000,000
BENEFICIALLY
OWNED BY
EACH ------- ==============================================
REPORTING 8. SHARED VOTING POWER
PERSON WITH
0
------- ==============================================
9. SOLE DISPOSITIVE POWER
1,000,000
------- ==============================================
10. SHARED DISPOSITIVE POWER
0
============ ===================================================================
11.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,000,000
===================================================================
============ ===================================================================
12.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
|-|
===================================================================
============ ===================================================================
13.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.4%
===================================================================
============ ===================================================================
14.
TYPE OF REPORTING PERSON
CO
============ ===================================================================
<PAGE>
- --------------------------- -------------------------
CUSIP No. 13D Page 3 of 14
871951 109
- --------------------------- -------------------------
============ ===================================================================
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (ENTITIES ONLY)
Siemens Aktiengesellschaft
===================================================================
============ ===================================================================
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)|_|
(b) X
===================================================================
============ ===================================================================
3.
SEC USE ONLY
===================================================================
============ ===================================================================
4.
SOURCE OF FUNDS
WC
===================================================================
============ ===================================================================
5.
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) OR 2(e)
|_|
===================================================================
============ ===================================================================
6.
CITIZENSHIP OR PLACE OF ORGANIZATION
Federal Republic of Germany
========================= ------- ==============================================
7. SOLE VOTING POWER
NUMBER OF
SHARES 1,000,000
BENEFICIALLY
OWNED BY
EACH ------- ==============================================
REPORTING 8. SHARED VOTING POWER
PERSON WITH
0
------- ==============================================
9 SOLE DISPOSITIVE POWER
1,000,000
------- ==============================================
10. SHARED DISPOSITIVE POWER
0
============ ===================================================================
11.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,000,000
===================================================================
============ ===================================================================
12.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES
|-|
===================================================================
============ ===================================================================
13.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.4%
===================================================================
============ ===================================================================
14.
TYPE OF REPORTING PERSON
CO
============ ===================================================================
<PAGE>
Item 1. Security and Issuer
The class of equity securities to which this Statement on Schedule 13D
relates is the common stock, par value $.001 per share (the "Common Stock"), of
Symphonix Devices, Inc. (the "Issuer"), a Delaware corporation, with its
principal executive offices located at 2331 Zanker Road, San Jose, California
95131-1107.
Item 2. Identity and Background
This statement is being filed by Siemens Audiologische Technik GmbH, a
corporation organized under the laws of the Federal Republic of Germany ("SAT")
and Siemens Aktiengesellschaft, a corporation organized under the laws of the
Federal Republic of Germany ("Siemens A.G.").
SAT has its principal office at Gebbertstrasse 125, D-91058 Erlangen,
Federal Republic of Germany. SAT's principal business is designing, developing,
manufacturing, purchasing, marketing, and selling hearing instruments and
related products for diagnosis of hearing impairment. SAT is a wholly-owned
subsidiary of Siemens A.G.
Siemens A.G. has its principal office at Wittelsbacherplatz 2, D-80333
Munich, Federal Republic of Germany. Siemens A.G.'s principal business is the
design, development, manufacture and marketing of a wide variety of electrical
and electronics systems.
The directors and executive officers of SAT and Siemens A.G. are set
forth on Schedules I and II, respectively, attached hereto. Schedules I and II
set forth the following information with respect to each such person:
i. name;
ii. business address (or residence address where indicated);
iii. present principal occupation or employment and the name,
principal business and address of any corporation or other
organization in which such employment is conducted; and
Page 4 of 14
<PAGE>
iv. citizenship.
During the last five years, neither SAT, Siemens A.G., nor any person named
in Schedule I or II attached hereto has been (a) convicted in a criminal
proceeding (excluding traffic violations or similar misdemeanors) or (b) a
party to a civil proceeding of a judicial or administrative body of
competent jurisdiction and as a result of such proceeding was or is subject
to a judgment, decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, federal or state securities
laws or finding any violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration
The aggregate amount of funds used by SAT to purchase the shares of
Common Stock as described in Item 4 hereof was $5,000,000. SAT used funds from
its working capital to make the purchase.
Item 4. Purpose of Transaction
On December 1, 1999, the Issuer and SAT entered into the Common Stock
Purchase Agreement (the "Purchase Agreement"), pursuant to which, on the same
day, SAT purchased 1,000,000 shares of Common Stock for $5,000,000.
SAT purchased the Common Stock for the purpose of making an investment
in the Issuer and not with the present intention of acquiring control of the
Issuer's business. Although upon purchase of the shares of Common Stock SAT
obtained the right to appoint one person to the Issuer's Board of Directors,
such right will not result in the Purchaser controlling the Board or the
Issuer's business. Assuming the conditions set forth in the Purchase Agreement
are satisfied, SAT also may acquire additional shares of Common Stock pursuant
to the terms of the Purchase Agreement, which terms are described in Item 6
below.
Page 5 of 14
<PAGE>
SAT from time to time may review its investment in the Issuer on the
basis of various factors, including the Issuer's business, financial condition,
results of operations and prospects, general economic and industry conditions,
the securities markets in general and those for the Issuer's securities in
particular, as well as other developments and other investment opportunities.
Based upon such review, SAT will take such actions in the future as SAT may deem
appropriate in light of the circumstances existing from time to time. If SAT
believes that further investment in the Issuer is attractive, whether because of
the market price of the Issuer's securities or otherwise, it may acquire shares
of Common Stock or other securities of the Issuer either pursuant to the
Purchase Agreement, in the open market or in privately negotiated transactions
(subject to any applicable restrictions in the Purchase Agreement on Purchaser's
ability to purchase additional shares of the Issuer's securities). Similarly,
depending on market and other factors, SAT may determine to dispose of some or
all of the shares of Common Stock currently owned by SAT or otherwise acquired
by SAT in the open market or in privately negotiated transactions (subject to
any applicable restrictions in the Purchase Agreement on Purchaser's ability to
dispose of shares of the Issuer's securities).
Except as set forth herein, SAT has not formulated any plans or proposals
which relate to or would result in: (a) the acquisition by any person of
additional securities of the Issuer or the disposition of securities of the
Issuer, (b) an extraordinary corporate transaction involving the Issuer or any
of its subsidiaries, (c) a sale or transfer of a material amount of the assets
of the Issuer or any of its subsidiaries, (d) any change in the present Board of
Directors or management of the Issuer, (e) any material change in the Issuer's
capitalization or dividend policy, (f) any other material change in the Issuer's
business or corporate structure, (g) any change in the Issuer's charter or
bylaws or other instrument's corresponding thereto or other action which may
impede the acquisition of control of the Issuer by any person, (h) causing a
class of the Issuer's securities to be deregistered or delisted, (i) a class of
equity securities of the Issuer becoming eligible for termination of
registration or (j) any action similar to any of those enumerated above.
Item 5. Interest in Securities of the Issuer
SAT purchased 1,000,000 newly-issued shares of Common Stock
from the Issuer on December 1, 1999, for an aggregate purchase price of
$5,000,000. The Issuer has advised Siemens that as of December 1, 1999 there
were 13,441,949 shares of Common Stock outstanding, including the 1,000,000
shares issued to SAT. Based on that information, SAT owns approximately 7.4% of
the issued and outstanding shares of Common Stock. Except as described herein,
neither SAT, Siemens A.G. nor any other person referred to in Schedules I and II
attached hereto has acquired or disposed of any shares of Common Stock during
the past sixty days. SAT has the sole right to vote or direct the vote and
dispose or direct the disposition of all the shares of Common Stock. No other
person is known to have the right to receive or the power to direct the receipt
of dividends from, or proceeds from the sale of, any of the Common Stock.
Siemens A.G. through its ownership of SAT, may be able to influence decisions
concerning the exercise of such power.
Page 6 of 14
<PAGE>
The Purchase Agreement provides that SAT shall be obligated to
purchase additional shares of Common Stock in the event that, on or prior to
April 30, 2001, the Issuer receives premarket approval from the United States
Food and Drug Administration (the "FDA") for the Issuer's Vibrant P and Vibrant
D soundbridges. In such event, SAT will purchase from the Issuer, for the
aggregate price of $5,000,000, the number of additional shares of Common Stock
determined by dividing $5,000,000 by the number equal to the average of the
closing sales price of the Common Stock for the forty trading days immediately
preceding the public announcement of FDA premarket approval for the Vibrant P
and Vibrant D soundbridges; provided that if the average closing price for such
period is equal to or greater than $7.00 but less than or equal to $10.00, then
the number by which the $5,000,000 will be divided shall be $7.00; and provided
further that if the average closing price is calculated to be greater than
$10.00, then the number by which the $5,000,000 will be divided shall be equal
to 0.70 multiplied by the average closing price of the Common Stock calculated
as set forth above, with the number by which the $5,000,000 will be divided
being subject to an overall maximum of $12.00. Notwithstanding the foregoing,
SAT will have no obligation to purchase any additional shares of Common Stock if
another person acquires 20% of the outstanding stock of the Issuer.
Page 7 of 14
<PAGE>
Pursuant to the Purchase Agreement, in the event the Issuer receives
FDA premarket approval for its Vibrant P and Vibrant D soundbridges, SAT will
have the right to purchase from the Issuer additional shares of Common Stock
constituting up to 20% of the outstanding voting stock of the Issuer, for a
price per share equal to the average closing price of the Common Stock for the
forty trading days immediately prior to SAT's giving notice to the Issuer that
it will purchase additional shares of Common Stock. SAT may exercise the right
to purchase additional shares of Common Stock until the earlier of either
November 1, 2004 or the termination by SAT of the Marketing and Distribution
Agreement due to the Issuer's default thereunder.
Pursuant to the Purchase Agreement, so long as SAT owns at least 5% of
the outstanding voting stock of the Issuer, if the Issuer issues any additional
shares of stock, SAT will have the right to purchase from the Issuer the number
of shares of such newly issued stock sufficient to maintain SAT's percentage
interest in the Issuer's outstanding stock.
Item 6. Contracts, Arrangements, Understandings or
Relationships with Respect to Securities of the Issuer.
As described in Item 4, SAT has purchased 1,000,000 shares of Common
Stock pursuant to the Purchase Agreement.
Pursuant to the Purchase Agreement, as long as SAT does not sell any shares
of the Issuer's voting stock, SAT is entitled to nominate one member of the
Issuer's Board of Directors. The Issuer shall include SAT's nominee to the Board
of Directors in the Issuer's slate of nominees recommended by the Board or
management to stockholders for election at annual stockholder meetings and the
Issuer shall use its best efforts to cause shares for which the Issuer's
management or directors hold proxies (or are otherwise entitled to vote) to vote
in favor of SAT's nominee to the Board. A person designated by SAT will be
appointed to the Issuer's Board of Directors no later than January 31, 2000.
The Purchase Agreement provides that SAT may require the Issuer to include
shares of Common Stock owned by SAT in registrations of Common Stock by the
Issuer. In addition, SAT has the right to require, on up to two occasions, that
the Issuer file a registration statement under the Securities Act of 1933 with
respect to shares of Common Stock owned by SAT. The foregoing registration
rights are exercisable after the earlier of November 30, 2004, the termination
by SAT of the Marketing and Distribution Agreement due to the Issuer's default
thereunder, or the acquisition by another person of more than 20% of the voting
stock of the Issuer.
The Purchase Agreement provides that, until the first to occur of a
change in control (as described in the Purchase Agreement) of the Issuer, a
third party's making a tender offer for the outstanding stock of the Issuer, a
tender offer by SAT or its affiliates for the outstanding stock of the Issuer
(which tender offer must first be approved by the board of directors of the
Issuer), or a third party's acquiring more than 20% of the outstanding voting
stock of the Issuer, SAT and its affiliates will not increase their percentage
interest in the outstanding voting stock of the Issuer above 20%, and SAT and
its affiliates will vote their shares in favor of nominees to the board of
directors of the Issuer in accordance with the recommendations of the board of
directors of the Issuer.
Page 8 of 14
<PAGE>
The Purchase Agreement further provides that, subject to certain
limited exceptions, transfers of beneficial ownership of the Common Stock by SAT
will be subject to the Issuer's right of first refusal.
The description of certain terms of the Purchase Agreement set forth
under Item 5 is incorporated in this Item 6 by reference.
The foregoing description is a summary of certain terms of the Purchase
Agreement and the Marketing and Distribution Agreement and is qualified in its
entirety by reference to such documents, which are attached as Exhibits 1 and 2.
Item 7. Material to be Filed as Exhibits.
Exhibit 7.1 Common Stock Purchase Agreement dated as of
December 1, 1999 between the Issuer and SAT.
Exhibit 7.2 Marketing and Distribution Agreement, dated as of
November 2, 1999, between the Issuer and SAT.
Exhibit 7.3 Certificate of Notary Public of Erlangen, Federal
Republic of Germany.
Page 9 of 14
<PAGE>
Signature
After reasonable inquiry and to the best of our knowledge and
belief, we certify that the information set forth in this Statement is true,
complete and correct.
December 1, 1999 SIEMENS AUDIOLOGISCHE TECHNIK GmbH
By: /s/ V. Chapero
__________________________
Name: V. Chapero
Title: Managing Director
By: /s/ H. Mehl
__________________________
Name: H. Mehl
Title: Managing Director
SIEMENS AKTIENGESELLSCHAFT
By: /s/ G. Steinhardt
__________________________
Name: G. Steinhardt
Title: Vice President
Medical Systems Group
By: /s/ W. Mueller - Huschke
__________________________
Name: W. Mueller - Huschke
Title: Corporate Legal Counsel
Page 10 of 14
<PAGE>
SCHEDULE I
The name and position of the executive officers and members of the board of
directors of Siemens Audiologische Technik GmbH are set forth below. Unless
otherwise noted, each of these persons are citizens of the Federal Republic of
Germany.
<TABLE>
<CAPTION>
Name and Citizenship Position with SAT and Principal Occupation Business Address
<S> <C> <C>
Dr. Robert Kugler Member of Management Board of SAT; Henkestrasse 127
Citizen of Austria Member of Management Board of D-91052 Erlangen
Medical Engineering Group of Siemens Federal Republic of Germany
AG
Mr. Gotz Steinhardt Member of Management Board of SAT; Henkestrasse 127
Member of Management Board of D-91052 Erlangen
Medical Engineering Group of Siemens Federal Republic of Germany
AG
Mr. Karl Heinz Midunsky Member of Management Board of SAT; Wittelsbacherplatz 2
Head of Corporate Mergers and D-80333 Munich
Acquisitions Department of Siemens AG Federal Republic of Germany
Dr. Valentin Chapero Managing Director of SAT Gebbertstrasse 125
Citizen of Spain D-91058 Erlangen
Federal Republic of Germany
Mr. Hans Mehl Managing Director of SAT Gebbertstrasse 125
D-91058 Erlangen
Federal Republic of Germany
Mr. Herbert Wolf Officer, Head of Research and Gebbertstrasse 125
Development of SAT D-91058 Erlangen
Federal Republic of Germany
</TABLE>
Page 11 of 14
<PAGE>
Schedule II
The name and position of each of the executive officers and
members of the Managing Board of Directors of Siemens A.G. are set forth below.
Each of these persons is a Member of the Managing Board of Directors of Siemens
AG and each of these persons is a citizen of the Federal Republic of Germany.
<TABLE>
<CAPTION>
Name Position with Siemens A.G. and Principal Business Address
Occupation
<S> <C> <C>
Dr. Heinrich von Pierer President and CEO, Wittelsbacherplatz 2
Head of Corporate Planning and Development D-80333 Munich
Department Federal Republic of
Germany
Dr. Volker Jung Special Responsibilities: Wittelsbacherplatz 2
Components, Information and D-80333 Munich
Communications Business Segments, Federal Republic of
Regions Africa, Middle East, C.I.S. Germany
Mr. Roland Koch Head of Information and Communication Hofmannstrasse 51
Networks Group D-81359 Munich
Federal Republic of
Germany
Dr. Edward G. Krubasik Special Responsibilities: Werner-von-Siemens-Strasse
Industry and Transportation Business 50
Segments D-91052 Erlangen
Federal Republic of
Germany
Mr. Heinz Joachim Neuburger Chief Financial Officer Wittelsbacherplatz 2
Head of Corporate Finance Department, D-80333 Munich
Special Responsibilities: Federal Republic of
Financial Services Germany
Prof. Peter Pribilla Head of Corporate Human Resources Wittelsbacherplatz 2
Department, D-80333 Munich
Special Responsibilities: Region the Federal Republic of
Americas Germany
Page 12 of 14
<PAGE>
Name Position with Siemens A.G. and Principal Business Address
Occupation
Mr. Jurgen Radomski Special Responsibilities: Werner-von-Siemens-Strasse
Health Care and Lightning Business 50
Segments, D-91052 Erlangen
Region Europe Federal Republic of
Germany
Dr. Claus Weyrich Head of Corporate Technology Department Otto-Hahn-Ring 6
D-81739 Munich
Federal Republic of
Germany
Dr. Gunther Wilhelm Special Responsibilities: Werner-von-Siemens-Strasse
Energy Business Segments, 50
Regions Asia, Australia D-91052 Erlangen
Federal Republic of
Germany
Dr. Klaus Wucherer Head of Automation and Drives Group Gleiwitzerstrasse 555
D-90475 Nuremberg
Federal Republic of
Germany
</TABLE>
Page 13 of 14
<PAGE>
Exhibit Index
Exhibit Page
Exhibit 7.1 Common Stock Purchase Agreement dated as of
November 30, 1999 between the Issuer and SAT.
Exhibit 7.2 Marketing and Distribution Agreement, dated
as of November 2, 1999, between the Issuer and SAT.
Exhibit 7.3 Certificate of Notary Public of Erlangen, Federal
Republic of Germany.
Page 14 of 14
EXHIBIT 7.1
SYMPHONIX DEVICES, INC.
COMMON STOCK PURCHASE AGREEMENT
DECEMBER 1, 1999
<PAGE>
TABLE OF CONTENTS
Page
----
Section 1 Definitions.........................................................1
Section 2 Purchase and Sale of the Common Shares..............................5
2.1 Purchase and Sale of the Common Shares at the Closing.............5
2.2 Purchase and Sale of the Common Shares at Second Closing..........6
Section 3 Representations and Warranties of the Company.......................7
3.1 Organization and Standing.........................................7
3.2 Corporate Power; Authorization....................................7
3.3 Issuance and Delivery.............................................7
3.4 SEC Documents; Financial Statements; Subsequent Events............8
3.5 Governmental Consents.............................................8
3.6 Exempt Transactions...............................................8
3.7 No Material Adverse Change........................................8
3.8 Intellectual Property.............................................9
3.9 Authorized Capital Stock..........................................9
3.10 Litigation........................................................10
3.11 Compliance With Other Instruments.................................10
3.12 Brokers or Finders................................................11
3.13 No Implied Representations........................................11
3.14 Properties........................................................11
3.15 Taxes.............................................................11
3.16 Transfer Taxes....................................................11
3.17 Insurance.........................................................11
3.18 Complete Copies of Materials......................................12
3.19 Representations Complete..........................................12
Section 4 Representations, Warranties and Covenants of the Purchaser..........12
4.1 Authorization.....................................................12
4.2 Investment Experience.............................................12
4.3 Investment Intent.................................................12
4.4 Registration or Exemption Requirements............................13
4.5 No Legal, Tax or Investment Advice................................13
Section 5 Conditions to Closing of the Purchaser..............................13
5.1 Conditions to Purchaser's Obligations at the Closing..............13
5.2 Conditions to the Purchaser's Obligations at the Second Closing...14
<PAGE>
TABLE OF CONTENTS
(continued)
Page
----
Section 6 Conditions to Company's Obligations.................................15
6.1 Conditions to Company's Obligations at the Closing................15
6.2 Conditions to Company's Obligations at the Second Closing.........15
Section 7 The Purchaser's Covenants and the Company's Rights..................16
7.1 The Purchaser's Standstill Obligations............................16
7.2 The Purchaser's Transfer Restrictions.............................17
7.3 The Company's Right of First Refusal..............................17
7.4 The Purchaser's Voting Obligations................................18
Section 8 Covenants of the Company and the Purchaser's Rights.................19
8.1 The Purchaser's Rights to Maintain................................19
8.2 The Purchaser's Board Representation Rights.......................21
8.3 The Purchaser's Registration Rights...............................22
8.4 The Purchaser's Right to Increase its Ownership Interest..........25
Section 9 Indemnification.....................................................26
9.1 Survival of Representations and Warranties........................26
9.2 Obligation to Indemnify...........................................27
9.3 Notice and Opportunity to Defend..................................27
Section 10 Miscellaneous......................................................28
10.1 Waivers and Amendments............................................28
10.2 Governing Law.....................................................28
10.3 Consent to Jurisdiction...........................................28
10.4 Release of Siemens Audiologische Technik and Siemens
Aktiengesellschaft ..............................................28
10.5 Waiver of Jury Trial; Trial Costs.................................28
10.6 Survival..........................................................29
10.7 Successors and Assigns............................................29
10.8 Entire Agreement..................................................29
10.9 Notices, etc......................................................29
10.10 Severability of this Agreement....................................30
10.11 Counterparts......................................................30
10.12 Further Assurances................................................30
10.13 Expenses..........................................................30
10.14 Currency..........................................................30
<PAGE>
SYMPHONIX DEVICES, INC.
COMMON STOCK PURCHASE AGREEMENT
This Agreement is made as of December 1, 1999 by and among Symphonix
Devices, Inc., a Delaware corporation (the "Company"), and Siemens Audiologische
Technik GmbH (the "Purchaser").
Section 1
Definitions
"Additional Shares" shall have the meaning set forth in Section 8.4(a)
below.
"Affiliate" shall have the meaning set forth in Rule 12b-2 of the rules
and regulations promulgated under the Exchange Act; provided, however, that for
purposes of this Agreement, the Purchaser and its Affiliates, on the one hand,
and the Company and its Affiliates, on the other, shall not be deemed to be
"Affiliates" of one another.
"Average Price" shall have the meaning set forth in Section 2.2(a) below.
"Beneficially Own" or "Beneficial Ownership" shall have the meaning set
forth in Rule 13d-3 of the rules and regulations promulgated under the Exchange
Act.
"Change in Control of the Company" shall mean any of the following: (i) a
merger, consolidation or other business combination or transaction to which the
Company is a party if the stockholders of the Company immediately prior to the
effective date of such merger, consolidation or other business combination or
transaction, as a result of such ownership of stock of the Company, have
Beneficial Ownership of voting securities representing less than 50% of the
Total Current Voting Power of the surviving corporation following such merger,
consolidation or other business combination or transaction; (ii) an acquisition
by any person, entity or 13D Group of direct or indirect Beneficial Ownership of
Voting Stock of the Company representing 20% or more of the Total Current Voting
Power of the Company; (iii) a sale of all or substantially all the assets of the
Company; or (iv) a liquidation or dissolution of the Company.
"Closing" shall have the meaning set forth in Section 2.1(b) below.
"Closing Date" shall have the meaning set forth in Section 2.1(b) below.
"Common Shares" shall mean the shares of Company Common Stock to be
purchased pursuant to Section 2 below.
"Company Common Stock" shall mean shares of the Common Stock of the
Company.
<PAGE>
"Company Controlled Corporation" shall mean a corporation of which the
Company owns not less than 80% of the outstanding voting power entitled to vote
in the election of directors of such corporation.
"Company Financing Issuance Notice" shall have the meaning set forth in
Section 8.1(b)(i)
"Disinterested Stockholders" shall mean any stockholder of the Company who
is not the Purchaser or an Affiliate of the Purchaser or a member of a 13D Group
in which Purchaser or an Affiliate of Purchaser is also a member.
"Exchange Act" shall mean the Securities Exchange Act of 1934, as amended.
"Fair Market Value" means, as of any date of determination, in the case of
Company Common Stock, the average of the closing sale prices of Company Common
Stock during the forty (40) trading days immediately preceding such date of
determination on Nasdaq or any comparable system then in use or, if no such
quotations are available, the fair market value of such security as of such date
of determination as determined in good faith by a majority of the Independent
Directors.
"FDA" shall mean the U.S. Food and Drug Administration.
"Financial Statements" shall have the meaning set forth in Section 3.4
below.
"HSR Act" shall mean the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended.
"Indemnified Party" shall have the meaning set forth in Section 8.3(e)(3)
below.
"Independent Director?Independent Director" shall mean a director of the
Company (i) who is not and has never been an officer or employee of the Company,
any Affiliate of the Company or of an entity that derived 10% or more of its
revenues in its most recent fiscal year from transactions involving the Company
or any Affiliate of the Company, (ii) who is not and has never been an officer
or employee and is not currently a director of Purchaser or any Affiliate of
Purchaser or of an entity that derived more than 10% of its revenues in its most
recent fiscal year from transactions involving Purchaser or any Affiliate of
Purchaser and (iii) who has no compensation, consulting or contracting
arrangement with the Company, Purchaser or their respective Affiliates or any
other entity such that a reasonable person would regard such director as likely
to be unduly influenced by management of the Company or Purchaser, respectively,
and shall, by definition, not include any Purchaser Director.
"Marketing and Distribution Agreement" shall mean that certain Marketing
and Distribution Agreement between the Company and Purchaser dated November 2,
1999.
"Milestone Certificate" shall mean a certificate signed by the President
or a Vice President of the Company stating that the Company has achieved the
milestone identified as the receipt of an approval order from the FDA for the
premarket approval application filed for the Company's Vibrant
-2-
<PAGE>
P and Vibrant D soundbridges (the "Approval Order"). The Milestone Certificate
shall also include a copy of the Approval Order. The Company shall deliver such
Milestone Certificate no later than ten days after receipt of the Approval
Order.
"Nasdaq" shall mean the Nasdaq Stock Market.
"New Securities" shall mean shares of Voting Stock or other
dividend-bearing common stock to be issued by the Company, either directly or as
a result of exercise, conversion or exchange of any Non-Voting Convertible
Securities by the holder(s) thereof, excluding any such shares to be issued (i)
upon exercise, conversion or exchange of any security convertible into or
exercisable or exchangeable for Voting Stock outstanding on the date of this
Agreement (including, but not limited to Non-Voting Convertible Securities
issued under the Company's 1994 Stock Option Plan and 1997 Employee Stock
Purchase Plan), (ii) upon exercise of any option, warrant or other right to
acquire any Voting Stock or Non-Voting Convertible Securities that was
previously subject to the Purchaser's right to maintain under Section 8.1 below,
or (iii) securities issued pursuant to the exercise by the Purchaser of its
rights pursuant to Section 8.1 below.
"Non-Voting Convertible Securities" shall mean any securities of the
Company which are convertible into, exchangeable for or otherwise exercisable to
acquire Voting Stock of the Company, including convertible securities, warrants,
rights or options to purchase Voting Stock of the Company.
"Purchase Price" shall have the meaning set forth in Section 8.1(a) below.
"Purchaser Director" shall mean a member of the Board of Directors of the
Company who is designated for such position by Purchaser in accordance with
Section 8.2 below.
"Purchaser's Financing Issuance Notice" shall have the meaning set forth
in Section 8.1(b)(ii).
"Purchaser's Other Issuances Notice" shall have the meaning set forth in
Section 8.1(c)(ii) below.
"Purchaser's Pro Rata Portion" shall mean (i) in the case of the issuance
of Voting Stock, that number of shares of Voting Stock to be issued which, if
purchased by the Purchaser, would result in the Purchaser maintaining its
percentage interest in the Total Current Voting Power of the Company in effect
immediately prior to such issuance of Voting Stock or (ii) in the case of the
issuance of any other stock other than Voting Stock or Non-Voting Convertible
Securities, that number of shares of such stock to be issued which, if Purchased
by the Purchaser, would result in the Purchaser maintaining its percentage
interest in the Total Outstanding Company Equity in effect immediately prior to
such issuance.
"Purchaser Tender Offer" shall mean a bona fide public tender offer
subject to the provisions of Regulation 14D when first commenced within the
meaning of Rule 14d-2(a) of the rules and regulations under the Exchange Act, by
the Purchaser or any Affiliate of the Purchaser (or any 13D Group that includes
Purchaser or any Affiliate of Purchaser) to purchase or exchange for cash or
-3-
<PAGE>
other consideration any Voting Stock and which consists of an offer to acquire
100% of the Total Current Voting Power of the Company then in effect (other than
Shares owned by the Purchaser or any Affiliate of the Purchaser) and is
conditioned (which condition may not be waived) on a majority of the shares of
Voting Stock held by Disinterested Stockholders being tendered and not withdrawn
with respect to such offer.
"Registration Expense" shall have the meaning set forth in Section 8.3(c)
below.
"Response Notice" shall have the meaning set forth in Section 7.3(a)(ii)
below.
"SEC" shall mean the U.S. Securities and Exchange Commission.
"SEC Documents" shall have the meaning set forth in Section 3.4 below.
"Second Closing" shall have the meaning set forth in Section 2.2(b) below.
"Second Closing Date" shall have the meaning set forth in Section 2.2(b)
below.
"Securities Act" shall mean the Securities Act of 1933, as amended.
"Selling Expenses" shall have the meaning set forth in Section 8.3(c)
below.
"Shares" shall mean any shares of Voting Stock that are Beneficially Owned
by the Purchaser, but specifically excluding any shares of Company Common Stock
subject to any Non-Voting Convertible Securities that have not yet been
exercised, converted or exchanged for Voting Stock.
"Standstill Limit" shall mean 20% of the Total Current Voting Power.
"Standstill Period" shall mean the period beginning on the Closing Date
and ending on the occurrence of a Standstill Termination Event.
"Standstill Reinstatement Event" shall mean the occurrence of either of
the following: (i) withdrawal or termination of a Third Party Tender Offer at
any time during which a Purchaser Tender Offer is not then pending or (ii)
withdrawal, termination, or material alteration of a Purchaser Tender Offer
other than an increase in price.
"Standstill Revised Limit" shall mean the percentage of the Total Current
Voting Power represented by all Shares held by the Purchaser as of the
occurrence of a Standstill Reinstatement Event.
"Standstill Termination Event" shall mean the earliest to occur of the
following: (i) a Change in Control of the Company, (ii) a Third Party Tender
Offer, (iii) a Purchaser Tender Offer, or (iv) any person who is not the
Purchaser or an Affiliate of the Purchaser or 13D Group to which the Purchaser
or an Affiliate of the Purchaser is a member has acquired any Voting Stock which
results in such person or 13D Group owning or having the right to acquire more
than 20% of the Total Current
-4-
<PAGE>
Voting Power of the Company; provided, however, that upon a Standstill
Reinstatement Event, if the Standstill Revised Limit is greater than the
Standstill Limit, then the Standstill Revised Limit shall thereafter be deemed
the Standstill Limit for all purposes hereunder.
"Third Party Tender Offer" shall mean a bona fide public tender offer
subject to the provisions of Regulation 14D when first commenced within the
meaning of Rule 14d-2(a) of the rules and regulations under the Exchange Act, by
a person or 13D Group (which is not made by and does not include the Purchaser
or any Affiliate of the Purchaser) to purchase or exchange for cash or other
consideration any Voting Stock and which consists of an offer to acquire 50% or
more of the then Total Current Voting Power of the Company.
"Total Current Voting Power" shall mean the total number of votes which
may be cast in the election of members of the Board of Directors of either the
Company or the surviving corporation of a merger to which the Company is a party
if all securities entitled to vote in the election of such directors are present
and voted.
"Total Outstanding Company Equity" shall mean the total number of shares
of outstanding capital stock of the Company, on a fully diluted basis assuming
the conversion, exchange or exercise of all outstanding securities, whether
vested or unvested, convertible, exchangeable or exercisable into or for Company
Common Stock.
"Transfer Notice" shall have the meaning set forth in Section 7.3(a)(i)
below.
"Voting Stock" shall mean shares of the Company Common Stock and any other
securities of the Company having the ordinary power to vote in the election of
members of the Board of Directors of the Company.
"13D Group" means any group of persons formed for the purpose of
acquiring, holding, voting or disposing of Voting Stock which would be required
under Section 13(d) of the Exchange Act, and the rules and regulations
promulgated thereunder, to file a statement on Schedule 13D pursuant to Rule
13d-1(a) or a Schedule 13G pursuant to Rule 13d-1(c) with the SEC as a "person"
within the meaning of Section 13(d)(3) of the Exchange Act if such group
beneficially owned Voting Stock representing more than 5% of any class of Voting
Stock then outstanding.
Section 2
Purchase and Sale of the Common Shares.
2.1 Purchase and Sale of the Common Shares at the Closing.
(a) Subject to the terms and conditions hereof, the Company shall
issue and sell to the Purchaser, and the Purchaser shall purchase from the
Company 1,000,000 Common Shares for a purchase price of $5.00 per share.
-5-
<PAGE>
(b) The closing of the purchase and sale of the 1,000,000 Common Shares
(the "Closing") shall be held at 10:00 a.m. on December 1, 1999 (the "Closing
Date"), at the offices of Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road,
Palo Alto, California 94304 or at such other time and place as the Company and
the Purchaser may agree.
(c) At the Closing, subject to the terms and conditions hereof, the Company
shall deliver to the Purchaser a certificate, representing 1,000,000 Common
Shares purchased by the Purchaser from the Company, dated the date of the
Closing, against payment of the purchase price therefor by wire transfer of
immediately available funds to the Company's bank account in the amount of
$5,000,000.
2.2 Purchase and Sale of the Common Shares at Second Closing.
(a) Subject to Section 2.2(c) below, the Company shall issue and
sell to the Purchaser, and the Purchaser shall purchase from the Company on
twenty (20) days prior written notice to the Purchaser, which notice shall
include the Milestone Certificate, the total number of Common Shares equal to
the quotient obtained by dividing $5,000,000 by (x), where (x) is equal to the
average of the closing sales prices of the Company Common Stock as reported by
Nasdaq for the forty (40) trading days immediately preceding the date of the
public announcement of the FDA grant of premarket approval for the Company's
Vibrant P and Vibrant D soundbridges (the "Average Price"), provided, however,
(i) if the Average Price is equal to or greater than $7.00 but less than or
equal to $10.00, then (x) shall be $7.00 or (ii) if the Average Price is greater
than $10.00, then (x) shall be equal to 0.70 multiplied by the Average Price.
Notwithstanding the foregoing, in no event shall (x) be greater than $12.00 per
share. The Purchaser shall not be required to purchase any fractional Common
Share. In the event the quotient obtained by dividing $5,000,000 by (x) is not a
whole number, the Purchaser shall purchase only that number of Common Shares
equal to the whole number portion of such quotient, at a price per share equal
to (x).
(b) The purchase and sale of the Common Shares pursuant to this paragraph
2.2 shall be consummated at a second closing (the "Second Closing"), which
Second Closing shall take place at the offices of Wilson Sonsini Goodrich &
Rosati, 650 Page Mill Road, Palo Alto, California 94304 at 10:00 a.m. on the
date twenty (20) calendar days after delivery by the Company of the Milestone
Certificate, the third (3rd) business day following the satisfaction of the
conditions contemplated by paragraph (d) of this Section 2.2, or at such other
time and place as the Company and the Purchaser may agree (the "Second Closing
Date"). At the Second Closing, the Company will deliver to the Purchaser a
certificate representing the Common Shares being purchased by the Purchaser at
the Second Closing against payment of the purchase price therefor by wire
transfer of immediately available funds to the Company's bank account in the
amount of $5,000,000. In the event of any stock split or stock dividend
occurring during the period from the date hereof to the Second Closing Date, the
purchase price of the Common Shares in the Second Closing and the numerical
parameters in paragraph 2.2(a) shall be adjusted by a factor equal to the
inverse ratio of the stock split or stock dividend.
-6-
<PAGE>
(c) Notwithstanding the foregoing, the Purchaser shall have no
obligation to purchase any Common Shares pursuant to this Section 2.2 if either
(i) the Company does not receive premarket approval for its Vibrant P and
Vibrant D soundbridges from the FDA on or prior to April 30, 2001, or (ii) at
any time following the Closing Date a third party acquires Beneficial Ownership
of greater than 20% of the Total Current Voting Power of the Company, or (iii)
if the Company does not deliver the Milestone Certificate to the Purchaser
within ten (10) days after issuance of the Approval Order.
(d) The obligations of the parties and issuance of the Common Shares
pursuant to this Section 2.2 shall be subject to compliance with all applicable
laws, including the HSR Act, and the requirements of Nasdaq and any applicable
stock exchange.
Section 3
Representations and Warranties of the Company
The Company represents and warrants to the Purchaser as follows:
3.1 Organization and Standing. The Company is a corporation duly organized
and validly existing under, and by virtue of, the laws of the State of Delaware
and is in good standing as a domestic corporation under the laws of said state,
and has the requisite corporate power and authority to own its properties and to
carry on its business as now being conducted. Other than as disclosed in
Schedule 3.1 hereto, the Company has no subsidiaries or direct or indirect
ownership in any firm, corporation or business which either, individually or in
the aggregate, is material to the business of the Company. The Company and each
of its subsidiaries is qualified to do business and is in good standing as a
foreign corporation in every jurisdiction in which its ownership of property or
conduct of business requires it so to be qualified and in which the failure to
so qualify would have a material adverse effect on the financial condition or
business of the Company as a whole.
3.2 Corporate Power; Authorization. The Company has all requisite legal
and corporate power and authority and has taken all requisite corporate action
to duly authorize, execute and deliver this Agreement, to sell and issue the
Common Shares and to carry out and perform all of its obligations under and
contemplated by this Agreement and the Marketing and Distribution Agreement.
This Agreement and the Marketing and Distribution Agreement have been duly
executed and delivered by an authorized officer of the Company and constitute
legal, valid and binding obligations of the Company, enforceable in accordance
with their terms, except as limited by applicable bankruptcy, insolvency,
reorganization or similar laws relating to or affecting the enforcement of
creditors' rights generally.
3.3 Issuance and Delivery. The Common Shares and the Additional Shares
have been duly authorized, and, when issued and delivered in compliance with
this Agreement, will be duly and validly issued and delivered and will be fully
paid, nonassessable and free and clear of all pledges, liens, encumbrances and
restrictions. No preemptive rights, or other rights to subscribe for or
purchase, exist with respect to the issuance and sale of the Common Shares by
the Company pursuant
-7-
<PAGE>
to this Agreement. No further approval or authority of the stockholders or the
Board of Directors of the Company will be required for the issuance and sale of
the Common Shares or the Additional Shares to be sold by the Company as
contemplated herein.
3.4 SEC Documents; Financial Statements; Subsequent Events. The Company
has filed in a timely manner all documents that the Company was required to file
with the SEC under Sections 13, 14(a) and 15(d) of the Exchange Act, during the
twelve (12) months preceding the date of this Agreement and all rules and
regulations thereunder. As of their respective filing dates, all documents filed
by the Company with the SEC (the "SEC Documents") complied in all material
respects with the requirements of the Exchange Act or the Securities Act, as
applicable and all rules and regulations thereunder. None of the SEC Documents
contained, as of their respective dates, any untrue statement of material fact
or omitted to state a material fact required to be stated therein or necessary
to make the statements made therein, in light of the circumstances under which
they were made, not misleading, and such SEC Documents, when read as a whole, do
not contain any untrue statements of a material fact and do not omit to state a
material fact necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading. The financial
statements of the Company included in the SEC Documents (the "Financial
Statements") comply in all material respects with applicable accounting
requirements and with the published rules and regulations of the SEC with
respect thereto. The Financial Statements have been prepared in accordance with
United States generally accepted accounting principles consistently applied and
fairly present the financial position of the Company and any subsidiaries at the
dates thereof and the results of the Company's operations and cash flows for the
periods then ended (subject, in the case of unaudited statements, to normal
adjustments).
3.5 Governmental Consents. No consent, approval, order or authorization
of, or registration, qualification, designation, declaration or filing with, any
federal, state, or local governmental authority on the part of the Company is
required in connection with the execution and delivery of this Agreement and the
consummation of the transactions contemplated by this Agreement except for (a)
the filing of a Form D with respect to the issuance of the Common Shares with
the SEC and (b) the filing of a Nasdaq National Market Notification Form
(pursuant to Rule 10b-17 promulgated under the Exchange Act) with Nasdaq, and
(c) in the case of the Second Closing or a closing pursuant to Section 8.4
hereof, the filing under the HSR Act, each of which will be filed in a timely
manner.
3.6 Exempt Transactions. Subject to the accuracy of the Purchaser's
representations and warranties in Section 4 of this Agreement, the offer, sale
and issuance of the Common Shares in conformity with the terms of this Agreement
constitute transactions exempt from the registration requirements of Section 5
of the Securities Act and from the registration or qualification requirements of
the laws of any applicable state or United States jurisdiction.
3.7 No Material Adverse Change. Except as otherwise disclosed herein,
since September 30, 1999, there have not been any changes in the assets,
liabilities, financial condition, business or operations of the Company from
that reflected in the Financial Statements except
-8-
<PAGE>
(i) changes in the ordinary course of business which have not been, either
individually or in the aggregate, materially adverse, and (ii) the Company's
continued incurrence of operating losses and negative cash flow.
3.8 Intellectual Property. The Company owns or possesses adequate rights
to use all patents, patent rights, inventions, trademarks, trade names,
copyrights, licenses, governmental authorizations, trade secrets and know-how
that are used or necessary for the conduct of its business as described in the
SEC Documents; except as disclosed on Schedule 3.8 hereto, neither the Company
nor any of its subsidiaries has received any notice of, or has any knowledge of,
any infringement of or conflict with asserted rights of others with respect to
any patent, patent right, invention, trademarks, trade names, copyrights,
licenses, governmental authorizations, trade secret or know-how that,
individually or in the aggregate, if the subject of an unfavorable decision,
ruling or finding, would have a material adverse effect on the condition
(financial or otherwise), earnings, operations or business of the Company and
its subsidiaries considered as a whole. To the best knowledge of the Company and
its subsidiaries, no product or service that is manufactured, marketed,
performed or sold by the Company or any of its subsidiaries violates any license
or infringes any intellectual property rights of another. There is no pending or
written threat of a claim or litigation against the Company or any of its
subsidiaries (nor to the Company's knowledge does there exist any basis
therefor) contesting the validity of, or right to use, any of the foregoing
intellectual property rights.
3.9 Authorized Capital Stock. The authorized capital stock of the Company
conforms, as of the dates for which such information is given, in all material
respects to the statements relating thereto contained in the SEC Documents. The
issued and outstanding shares of capital stock of the Company have been duly
authorized, validly issued and are fully paid and nonassessable; except as set
forth or referred to in the SEC Documents, no warrants, options or other rights
to purchase, agreements or other obligations to issue, or agreements or other
rights to convert any obligation into, any shares of capital stock of the
Company have been granted or entered into by the Company. All of the above
securities of the Company were issued in compliance with all applicable federal
and state securities laws and were not issued in violation of or subject to any
preemptive rights or other rights to subscribe for or purchase securities.
Except as provided in this Agreement, no holder of any security of the Company
is entitled to any preemptive or similar rights to purchase any securities of
the Company. The authorized capital stock of the Company consists of 50,000,000
shares of common stock, par value $0.001 per share, of which at September 30,
1999, 12,402,460 shares were issued and outstanding, and 5,000,000 shares of
preferred stock par value $0.001 per share, none of which are outstanding. As of
September 30, 1999, the Company has reserved a total of 275,000 shares of
Company Common Stock for issuance under its 1997 Employee Stock Purchase Plan,
of which, at September 30, 1999, 64,613 shares have been issued pursuant to
purchases under such plan. As of September 30, 1999, the Company has reserved a
total of 3,499,273 shares of Company Common Stock for issuance under its 1994
Stock Option Plan, of which, at September 30, 1999, 1,371,571 shares of Company
Common Stock are duly reserved for issuance upon exercise of outstanding
options. As of September 30, 1999, 33,611 shares of Company Common Stock are
reserved for issuance upon exercise of other options, warrants and rights held
by other parties, and a list of the holders of such options, warrants and rights
is set forth on Schedule 3.9 hereto, together
-9-
<PAGE>
with the number of shares of either Company Common Stock or preferred stock
issuable upon exercise of each such option, warrant or right. Set forth on
Schedule 3.9 hereto, to the Company's best knowledge, is a list of each record
and beneficial holder of 5% or more of the Company Common Stock as of September
30, 1999, including the name, address and number of shares of Company Common
Stock held by each such holder. Except as provided or described in this
Agreement or in the Schedules hereto, there are no other options, warrants,
conversion privileges, convertible securities or other contractual rights
presently outstanding to purchase or otherwise acquire any authorized but
unissued shares of any of the Company's or any of its subsidiaries' capital
stock or other securities. Except as provided in this Agreement or in the
Schedules hereto, there are no preemptive or similar rights to purchase or
otherwise acquire shares of capital stock of the Company or any subsidiary,
whether pursuant to law, the certificates of incorporation or bylaws of the
Company or any of its subsidiaries, or any agreement or instrument. The Common
Shares to be purchased at the Closing shall represent approximately 7.46% of the
Total Current Voting Power, based upon a total of 13,441,949 shares of Common
Stock outstanding as of October 31, 1999 (such number includes the 1,000,000
shares to be purchased pursuant to Section 2 above and 39,489 shares issued
under the Company's 1997 Employee Stock Purchase Plan).
3.10 Litigation. There are no actions, suits, proceedings or
investigations pending or, to the best of the Company's knowledge, threatened
against the Company or any of its subsidiaries or properties before or by any
court or arbitrator or any governmental body, agency or official in which there
is a reasonable likelihood (in the judgment of the Company) of an adverse
decision that (a) would have a material adverse effect on the Company's
properties or assets or the business of the Company as presently conducted or
proposed to be conducted or (b) would impair the ability of the Company to
perform in any material respect its obligations under this Agreement. The
Company is not in default with respect to any judgment, order or decree of any
court or governmental agency or instrumentality which, individually or in the
aggregate, would have a material adverse effect on the assets, properties or
business of the Company.
3.11 Compliance With Other Instruments. The business and operations of the
Company and its subsidiaries have been and are being conducted in accordance
with all applicable laws, rules and regulations of all governmental authorities,
except for such violations of applicable laws, rules and regulations which would
not, individually or in the aggregate, have a material adverse effect on the
assets, properties, financial condition or business of the Company. Neither the
execution and delivery of, nor the performance or compliance with, this
Agreement and the transactions contemplated hereby, will, with or without the
giving of notice or the passage of time, (i) result in any breach of, or
constitute a default under, or result in the imposition of any lien or
encumbrance upon any asset or property of the Company pursuant to, any agreement
or other instrument to which the Company is a party or by which it or any of its
properties, assets or rights is bound or affected, except for such breach or
default or the imposition of any such lien or encumbrance which, either
individually or in the aggregate, would not have a material adverse effect on
the assets, properties, financial condition or business of the Company or (ii)
violate the Certificate of Incorporation or Bylaws of the Company, or any
applicable law, rule regulation, judgment, order or decree. The Company is not
in violation of its Certificate of Incorporation or Bylaws nor in violation of,
or in default under, any lien,
-10-
<PAGE>
indenture, mortgage, lease, agreement, instrument, commitment or arrangement,
except for such defaults which would not, individually or in the aggregate, have
a material adverse effect on the assets, properties, financial condition or
business of the Company, or subject to any restriction which would prohibit the
Company from entering into or performing its obligations under this Agreement.
Except as set forth on Schedule 3.11 hereto, neither the Company nor any
subsidiary of the Company has granted any right or authorization to any third
party to develop, manufacture, use, market or service the Company's products
that would conflict with the Company's obligations under the Marketing and
Distribution Agreement.
3.12 Brokers or Finders. No person, firm or corporation has or will have,
as a result of any act or omission of the Company, any right, interest or valid
claim against the Purchaser for any commission, fee or other compensation as a
finder or broker in connection with the transactions contemplated by this
Agreement.
3.13 No Implied Representations. All of the Company's representations and
warranties are contained in this Agreement and no other representations or
warranties by the Company shall be implied.
3.14 Properties. The Company has good and marketable title to all the
properties and assets reflected as owned in the financial statements included in
the SEC Documents, subject to no lien, mortgage, pledge, charge or encumbrance
of any kind except (i) those, if any, reflected in such financial statements, or
(ii) those which are not material in amount and do not adversely affect the use
made and promised to be made of such property by the Company and its
subsidiaries. The Company and any applicable subsidiary holds its leased
properties under valid and binding leases, with such exceptions as are not
materially significant in relation to the business of the Company and the
subsidiaries.
3.15 Taxes. The Company and its subsidiaries have filed all necessary
federal, state and foreign income and franchise tax returns and have paid or
accrued all taxes shown as due thereon, all of such tax returns are true and
complete in all material respects, and the Company has no knowledge of any tax
deficiency which has been or might be asserted or threatened against the Company
or its subsidiaries which could materially and adversely affect the business,
operations or properties of the Company and its subsidiaries.
3.16 Transfer Taxes. On the Closing Date and the Second Closing Date, and
any closing under Section 8 hereof, all stock transfer or other taxes (other
than income taxes) which are required to be paid in connection with the sale and
transfer of the Common Shares to be sold to the Purchaser hereunder will be, or
will have been, fully paid or provided for by the Company and all laws imposing
such taxes will be or will have been complied with fully.
3.17 Insurance. Each of the Company and its subsidiaries maintains
insurance of the types and in the amounts generally deemed adequate for its
business, including, but not limited to, insurance covering all real and
personal property owned or leased by the Company and its subsidiaries against
-11-
<PAGE>
theft, damage, destruction, acts of vandalism and all other risks customarily
insured against, all of which insurance is in full force and effect.
3.18 Complete Copies of Materials. The Company has delivered or made
available true and complete copies of each document (or summaries of same) or
has indicated that no such document exists with respect to all documents
relating to the Company which Purchaser or its counsel have requested in writing
to review in connection with this Agreement, and the transactions contemplated
hereby including, without limitation, true and complete copies of certain of the
documents provided to the Food and Drug Administration in connection with the
filing of the Company's PMA application.
3.19 Representations Complete. None of the representations or warranties
made by the Company (as modified by the Disclosure Schedules) in this Section 3,
nor any statement made in any schedule or certificate furnished by the Company
pursuant to this Agreement contains or will contain at the Closing, any untrue
statement of a material fact, or omits or will omit at the Closing to state any
material fact necessary in order to make the statements contained herein or
therein, in the light of the circumstances under which made, not misleading.
Section 4
Representations, Warranties and Covenants of the Purchaser
The Purchaser hereby represents and warrants to the Company as follows:
4.1 Authorization. (i) The Purchaser has all requisite legal and corporate
or other power and capacity and has taken all requisite corporate or other
action to execute and deliver this Agreement, to purchase the Common Shares to
be purchased by it and to carry out and perform all of its obligations under
this Agreement; and (ii) this Agreement constitutes the legal, valid and binding
obligation of the Purchaser, enforceable in accordance with its terms, except
(a) as limited by applicable bankruptcy, insolvency, reorganization, or similar
laws relating to or affecting the enforcement of creditors' rights generally and
(b) as limited by equitable principles generally.
4.2 Investment Experience. The Purchaser is an "accredited Purchaser" as
defined in Rule 501(a) under the Securities Act. The Purchaser is aware of the
Company's business affairs and financial condition and has had access to and has
acquired sufficient information about the Company to reach an informed and
knowledgeable decision to acquire the Securities. The Purchaser has such
business and financial experience as is required to give it the capacity to
protect its own interests in connection with the purchase of the Common Shares.
4.3 Investment Intent. The Purchaser is purchasing the Common Shares for
its own account as principal, for investment purposes only, and not with a
present view to, or for, resale, distribution or fractionalization thereof, in
whole or in part, within the meaning of the Securities Act. The Purchaser
understands that its acquisition of the Common Shares has not been registered
under
-12-
<PAGE>
the Securities Act or registered or qualified under any state securities law in
reliance on specific exemptions therefrom, which exemptions may depend upon,
among other things, the bona fide nature of the Purchaser's investment intent as
expressed herein. The Purchaser will not, directly or indirectly, offer, sell,
pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase
or otherwise acquire or take a pledge of) any of the Common Shares, except in
compliance with the terms of this Agreement and the Securities Act, and the
rules and regulations promulgated thereunder.
4.4 Registration or Exemption Requirements. The Purchaser further
acknowledges and understands that the Common Shares may not be resold or
otherwise transferred except in a transaction registered under the Securities
Act or unless an exemption from such registration is available. The Purchaser
understands that the certificate(s) evidencing the Common Shares will be
imprinted with a legend that prohibits the transfer of such securities unless
(i) they are registered or such registration is not required, and (ii) if the
transfer is pursuant to an exemption from registration under the Securities Act
and, if the Company shall so request in writing, an opinion of counsel
reasonably satisfactory to the Company is obtained to the effect that the
transaction is so exempt.
4.5 No Legal, Tax or Investment Advice. The Purchaser understands that
nothing in this Agreement or any other materials presented to the Purchaser in
connection with the purchase of the Common Shares constitutes legal, tax or
investment advice. The Purchaser has consulted such legal, tax and investment
advisors as it, in its sole discretion, has deemed necessary or appropriate in
connection with its purchase of the Common Shares.
Section 5
Conditions to Closing of the Purchaser
5.1 Conditions to Purchaser's Obligations at the Closing. The Purchaser's
obligation to purchase the Common Shares at the Closing under this Agreement is
subject to the fulfillment on or prior to the Closing Date of the following
conditions, any of which may be waived in whole or in part by the Purchaser:
(a) Representations and Warranties True. The representations and
warranties made by the Company in Section 3 hereof shall be true and correct on
the Closing Date with the same force and effect as if they had been made on and
as of said date.
(b) Covenants. All covenants, agreements and conditions contained in
this Agreement to be performed by the Company on or prior to the Closing Date
shall have been performed or complied with.
(c) Consents. The Company shall have obtained all consents, permits
and waivers necessary to consummate the transactions contemplated by this
Agreement which need to be obtained prior to the Closing.
-13-
<PAGE>
(d) Opinion of the Company's Counsel. The Purchaser shall have
received from Wilson Sonsini Goodrich & Rosati ("WSG&R"), counsel to the
Company, an opinion letter addressed to the Purchaser substantially in the form
attached as Exhibit A dated as of the Closing Date.
(e) Compliance Certificate. The Company shall have delivered to the
Purchaser a certificate of the Company, executed by the President or Chief
Financial Officer of the Company and dated as of the Closing Date, certifying to
the fulfillment of the conditions specified in Sections 5.1(a), (b) and (c).
(f) Marketing and Distribution Agreement. The Marketing and
Distribution Agreement shall have been executed by the Company.
(g) Compliance with Laws. The purchase of the Common Shares by the
Purchaser hereunder shall be legally permitted by all laws and regulations to
which the Purchaser or the Company are subject.
(h) Corporate Authorizations. Purchaser shall have received (i)
certified copies of the resolutions adopted by the Company's Board of Directors
authorizing the execution, delivery and performance of this Agreement and the
Marketing and Distribution Agreement, and (ii) copies of the Company's
Certificate of Incorporation and Bylaws, as in effect on the Closing Date.
(i) Due Diligence. Purchaser shall have completed its due diligence
review of the Company.
5.2 Conditions to the Purchaser's Obligations at the Second Closing. The
Purchaser's obligation to purchase the Common Shares at the Second Closing under
this Agreement is subject to the fulfillment on or prior to the Second Closing
Date of the following conditions, any of which may be waived in whole or in part
by the Purchaser:
(a) Representations and Warranties True. The representations and
warranties made by the Company in Section 3 hereof shall be true and correct
(other than the representations in Section 3.7 which shall be true and correct
in all material respects only as of the Closing Date) on the Second Closing Date
with the same force and effect as if they had been made on and as of said date.
(b) Covenants. All covenants, agreements and conditions contained in
this Agreement to be performed by the Company on or prior to the Second Closing
Date shall have been performed or complied with including, without limitation,
delivery of the Milestone Certificate.
(c) Consents. The Company shall have obtained all consents, permits
and waivers necessary or appropriate for consummation of the transactions
contemplated by this Agreement which need to be obtained prior to the Second
Closing.
-14-
<PAGE>
(d) Compliance Certificate. The Company shall have delivered to the
Purchaser a certificate of the Company, executed by the President or Chief
Financial Officer of the Company and dated as of the Second Closing Date,
certifying to the fulfillment of the conditions specified in Sections 5.2(a) and
(b).
(e) Compliance with Laws. The purchase of the Common Shares by the
Purchaser hereunder shall be legally permitted by all laws and regulations to
which the Purchaser or the Company are subject.
(f) Opinion of WSG&R. The Purchaser shall have received from WSG&R
an opinion letter addressed to the Purchaser substantially in the form attached
as Exhibit A dated as of the Second Closing Date.
Section 6
Conditions to Company's Obligations.
6.1 Conditions to Company's Obligations at the Closing. The Company's
obligation to sell and issue the Common Shares at the Closing is subject to the
fulfillment on or prior to the Closing Date of the following conditions, any of
which may be waived in whole or in part by the Company:
(a) Representations and Warranties True. The representations and
warranties made by the Purchaser herein shall be true and correct on the Closing
Date with the same force and effect as if they had been made on and as of the
same date.
(b) Consents. The Company shall have obtained all consents, permits
and waivers necessary or appropriate for consummation of the transactions
contemplated by this Agreement which need to be obtained prior to the Closing.
(c) Marketing and Distribution Agreement. The Marketing and
Distribution Agreement shall have been executed by the Purchaser.
(d) Compliance with all Laws. At the Closing, the purchase of the
Common Shares by the Purchaser hereunder shall be legally permitted by all laws
and regulations to which the Purchaser or the Company are subject.
6.2 Conditions to Company's Obligations at the Second Closing. The
Company's obligation to sell and issue the Common Shares at the Second Closing
is subject to the fulfillment on or prior to the Second Closing Date of the
following conditions, any of which may be waived in whole or in part by the
Company:
(a) Representations and Warranties True. The representations and
warranties made by the Purchaser herein shall be true and correct on the Second
Closing Date with the same force and effect as if they had been made on and as
of the same date.
-15-
<PAGE>
(b) Consents. The Company shall have obtained all consents, permits
and waivers necessary or appropriate for consummation of the transactions
contemplated by this Agreement which need to be obtained prior to the Second
Closing.
(c) Compliance with all Laws. At the Second Closing, the purchase of
the Common Shares by the Purchaser hereunder shall be legally permitted by all
laws and regulations to which the Purchaser or the Company are subject.
Section 7
The Purchaser's Covenants and the Company's Rights
7.1 The Purchaser's Standstill Obligations
(a) Notwithstanding anything to the contrary contained herein and
only during the Standstill Period, none of the Purchaser, any Affiliate of the
Purchaser or any 13D Group of which Purchaser or any of its Affiliates is a
member shall, directly or indirectly, acquire or Beneficially Own Voting Stock
or authorize or make a tender offer, exchange offer or other offer therefor, if
the effect of such acquisition would be to increase the percentage of Total
Current Voting Power represented by all Shares Beneficially Owned by the
Purchaser to more than the Standstill Limit, provided that, the foregoing shall
not prohibit the Purchaser and/or any of its Affiliates from making a Purchaser
Tender Offer during the Standstill Period that has been approved by the Board of
Directors of the Company.
(b) The Purchaser shall not be deemed to have violated its covenants
under this Section 7.1 by virtue of any increase in the aggregate percentage of
the Total Current Voting Power of the Company represented by Shares Beneficially
Owned by the Purchaser or its Affiliates if such increase is the result of a
recapitalization of the Company, a repurchase of securities by the Company or
other actions taken by the Company or any of the Company's Affiliates that have
the effect of reducing the Total Current Voting Power.
(c) All of the Purchaser's acquisitions of Shares during the
Standstill Period shall comply with applicable federal and state securities laws
and be subject to the provisions of this Agreement.
(d) During the Standstill Period, the Purchaser shall not solicit
proxies with respect to any Voting Stock, nor shall it become a "participant" in
any "election contest" (as such terms are used in Rule 14(a)-11 of Regulation
14A promulgated under the Exchange Act) relating to the election of directors of
the Company. Purchaser shall not be deemed to be such "participant" merely by
reason of the membership of the Purchaser Director on the Company's Board of
Directors pursuant to the terms of this Agreement.
(e) During the Standstill Period, the Purchaser shall not deposit
any shares of Voting Stock in a voting trust or, except as otherwise provided or
contemplated herein (including
-16-
<PAGE>
Section 7.4 hereof), or subject any Voting Stock to any arrangement or agreement
with any third party with respect to the voting of such Voting Stock.
(f) During the Standstill Period, the Purchaser shall not join a 13D
Group, partnership, limited partnership, syndicate or other group, or otherwise
act in concert with any third person for the purpose of acquiring, holding,
voting or disposing of Voting Stock or Non-Voting Convertible Securities, unless
the joining of such group is in connection with a Purchaser Tender Offer
approved by the Board of Directors of the Company.
7.2 The Purchaser's Transfer Restrictions.
(a) Unless the Purchaser Beneficially Owns less than 5% of the Total
Current Voting Power or until the Purchaser owns at least 90% of the Total
Current Voting Power, the Purchaser shall not, directly or indirectly, sell,
transfer, pledge, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to
purchase or otherwise dispose of, any Shares or Non-Voting Convertible
Securities except: (i) to the Company, (ii) to a Company Controlled Corporation,
(iii) in response to a Third Party Tender Offer which is not opposed by the
Board of Directors of the Company within the time such Board is required,
pursuant to the rules and regulations promulgated under the Exchange Act, to
advise Company stockholders of such Board's position on such offer, (iv)
following the earlier of (A) November 1, 2004 and (B) any termination by the
Purchaser (not the Company) of the Marketing and Distribution Agreement pursuant
to Section 10 thereof, (v) following the acquisition by a person or 13D Group
(which is not and does not include the Purchaser or any affiliate of the
Purchaser) of more than 20% of the Total Current Voting Power of the Company,
(vi) pursuant to an offering of Shares registered under the provisions of
Section 8.3 hereof; or (vii) pursuant to Rule 144 under the Securities Act but
only if such transaction (A) is in compliance with the volume limitations under
Rule 144(e) and (B) does not occur prior to the later of two years from the
Closing.
(b) Any attempted sale, transfer or other disposition by Purchaser
which is not in compliance with this Section 7.2 shall be null and void.
7.3 The Company's Right of First Refusal.
(a) Prior to the Purchaser effecting any sale, transfer or other
disposition of Shares or Non-Voting Convertible Securities in a private
placement transaction exempt from the registration requirements of the
Securities Act other than the transactions specified in Sections 7.2(a)(i),
(ii), (iii), (v), (vi) and (vii) above, the Company shall have a first refusal
right to purchase such Shares or Non-Voting Convertible Securities on the
following terms and conditions:
(i) The Purchaser shall give prior notice (the "Transfer
Notice") to the Company in writing of such intention, specifying the name of the
proposed purchaser or transferee, the number of Shares or Non-Voting Convertible
Securities proposed to be sold or transferred, the
-17-
<PAGE>
proposed price therefor and the other material terms upon which such disposition
is proposed to be made.
(ii) The Company shall have the right, exercisable by written
notice given by the Company to the Purchaser within ten (10) business days after
receipt of such Transfer Notice (the "Response Notice"), to purchase all, but
not less than all the Shares or Non-Voting Convertible Securities specified in
such Transfer Notice for cash at the price per share specified in the Transfer
Notice.
(iii) If the Company exercises its right of first refusal
hereunder, the closing of the purchase of the Shares or Non-Voting Convertible
Securities with respect to which such right has been exercised shall take place
within sixty (60) calendar days after the Company gives the Response Notice to
the Purchaser which period shall be extended, if necessary, to comply with
applicable laws and regulations. Upon exercise of its right of first refusal,
the Company and the Purchaser shall be legally obligated to consummate the
purchase and sale contemplated thereby and shall use their best efforts to
secure any approvals required in connection therewith.
(iv) If the Company does not exercise its right of first
refusal hereunder within the time specified for such exercise, the Purchaser
shall be free, during the period of ninety (90) calendar days following the
expiration of such time for exercise, to sell the Shares or Non-Voting
Convertible Securities specified in such Transfer Notice to the proposed
purchaser or transferee specified in such Transfer Notice and on terms not
materially less favorable to the Purchaser than the terms specified in such
Transfer Notice, which period shall be extended, if necessary, to comply with
applicable laws and regulations.
(b) The Company may assign its right of first refusal hereunder to
any other person or persons.
7.4 The Purchaser's Voting Obligations.
(a) The Purchaser shall take such action as may be required so that
all shares of Voting Stock Beneficially Owned by the Purchaser are voted for or
cast in favor of: (i) during the Standstill Period, nominees to the Board of
Directors of the Company in accordance with the joint recommendations of
management of the Company and a majority of the Board of Directors of the
Company, (ii) increases in the authorized capital stock of the Company and
amendments to stock option plans and employee stock purchase plans, in each case
approved by the Company's Board of Directors, and (iii) all matters approved by
the Purchaser Director whether such matters are submitted to a vote, action by
written consent or other approval of the holders of Voting Stock of the Company.
(b) Except as set forth in paragraph (a) above, nothing in this
Agreement shall preclude the Purchaser from voting shares of Voting Stock which
it Beneficially Owns in such manner as the Purchaser determines, in its sole
discretion, on any matter presented to the holders of Voting Stock for a vote,
consent or other approval; provided, however, that, in connection with any
merger, consolidation or other reorganization (i) which is approved by the
Company's Board of Directors, (ii)
-18-
<PAGE>
which is intended to qualify for pooling-of-interests accounting treatment, and
(iii) in connection with which the Purchaser has not exercised its appraisal
rights, Purchaser hereby covenants to enter into a standard affiliate lock-up
agreement if requested by the Company, regardless of the manner in which the
Purchaser may have voted or cast Shares of Voting Stock Beneficially Owned by
the Purchaser with respect to such transaction.
(c) So long as the Purchaser Beneficially Owns at least 5% of the
Total Current Voting Power, the Purchaser, as the holder of Shares, shall be
present, in person or by proxy, at all meetings of stockholders of the Company
so that all shares of Voting Stock held by the Purchaser may be counted for
purposes of determining the presence of a quorum at such meetings.
Section 8
Covenants of the Company and the Purchaser's Rights
8.1 The Purchaser's Rights to Maintain.
(a) In General. During the Standstill Period, provided that the
Purchaser Beneficially Owns at least 5% of the Total Current Voting Power, if
the percentage interest of the Purchaser in the Total Outstanding Company Equity
is or would be reduced at any time as a result of an issuance of New Securities,
the Purchaser shall have the right to purchase for cash the Purchaser's Pro Rata
Portion, in whole or in part, at an aggregate purchase price equal to the
product of the price per share at which such New Securities were or will be sold
in such issuance (a price per share as determined in accordance with subsection
(b) below), multiplied by the Purchaser's Pro Rata Portion or any part thereof
(the "Purchase Price").
(b) Financing Issuances.
(i) No less than ten (10), and no more than thirty (30),
calendar days prior to the issuance and sale of any New Securities for cash
consideration in a financing transaction (which shall not include any
transaction specifically described in subsection (c) below), the Company shall
notify the Purchaser of the Company's intention to make such issuance by written
dated notice (the "Company's Financing Issuance Notice") setting forth the
number and type of New Securities and the calculation of the Purchaser's Pro
Rata Portion.
(ii) Within fourteen (14) calendar days after receipt by the
Purchaser of the Company's Financing Issuance Notice, the Purchaser shall notify
the Company by written notice (the "Purchaser's Financing Issuance Notice")
stating whether the Purchaser desires to buy the Purchaser's Pro Rata Portion,
or any part thereof, for the Purchase Price.
(iii) If the Company issues and sells the New Securities in
the financing transaction, then the Purchaser shall be obligated to purchase (if
it has elected to exercise its right to maintain in the Purchaser's Financing
Issuance Notice) the Purchaser's Pro Rata Portion (or part
-19-
<PAGE>
thereof) for the Purchase Price with such Purchase Price based on the price per
share paid by the ultimate investors in the financing. The closing of any
purchases pursuant to this Section 8.1(b) shall take place contemporaneously
with such financing, subject to the provisions of paragraph (d) below. If the
Purchaser either (A) does not deliver a Purchaser's Financing Issuance Notice
within the time periods specified above or (B) elects in the Purchaser's
Financing Issuance Notice not to purchase the Purchaser's Pro Rata Portion or
any part thereof the Company shall not be obligated to sell to the Purchaser the
Purchaser's Pro Rata Portion.
(iv) The purchase price per share at which the Purchaser shall
be entitled to purchase the Purchaser's Pro Rata Portion shall be determined as
follows:
(1) If the event giving rise to the Purchaser's rights
is a sale or issuance of New Securities for cash or property, including, without
limitation, for securities or assets or by way of merger in connection with the
acquisition of another company, the price shall be the price per share specified
in the agreement relating to such issuance, or if no such price is specified,
the Fair Market Value of the New Securities determined as of the date of
issuance and sale of such New Securities.
(2) If the event giving rise to the Purchaser's rights
is an issuance of New Securities upon conversion of any security convertible
into or exchangeable for Common Stock or upon exercise of any option, warrant or
right to acquire any New Securities, the price shall be the exercise price per
share of such New Securities determined as of the date of such conversion or
exercise plus a pro-rata portion of the premium paid for the underlying option,
warrant or right.
(3) If the event giving rise to the Purchaser's rights
is an underwritten public offering or an institutional private placement, the
price shall be the price per share at which the New Securities were sold by the
Company.
(4) In all other cases, the price shall be the Fair
Market Value of the New Securities determined as of the date of the issuance and
sale of such New Securities.
(c) Other Issuances.
(i) No more than ten (10) calendar days after each one-year
anniversary of the date of this Agreement (until the termination of the
Standstill Period), the Company shall notify the Purchaser of the number of New
Securities issued pursuant to the Company's employee stock plans, purchase plans
or other stock plans for the benefit of employees, directors, officers,
consultants or others during such one year period by written dated notice (the
"Company's Other Issuances Notice") setting forth the number and type of New
Securities (such number to be net of any New Securities returned to an option
plan). In the case of New Securities that are stock options issued pursuant to a
Company employee stock option plan, the Purchaser's right to maintain under this
subsection (c) shall relate to the Voting Stock underlying such stock options
and the Purchase Price of such Voting Stock shall be the weighted average
exercise price of such stock options regardless of the net effect of any New
Securities returned to an option plan.
-20-
<PAGE>
(ii) Within fourteen (14) calendar days after receipt by the
Purchaser of the Company's Other Issuance Notice, the Purchaser shall notify the
Company by written notice (the "Purchaser's Other Issuances Notice") stating
whether the Purchaser desires to buy Purchaser's Pro Rata Portion of such New
Securities. If Purchaser elects to purchase such Pro Rata Portion, then the
closing of such transaction shall take place within three (3) business days
after the Company's receipt of such notice in accordance with subsection (d)
below.
(d) Closing; Other Matters.
(i) The purchase and sale of any New Securities pursuant to
this Section 8.1 shall take place at the offices of the Company set forth in
this Agreement at 10:00 a.m. on the earlier of the: (A) closing date specified
in the applicable subsection of this Section 8.1 or (B) the third (3rd) business
day following the expiration or early termination of all waiting periods imposed
on such purchase and sale by the HSR Act, or at such other time and place as the
Company and the Purchaser may agree.
(ii) The Company and the Purchaser shall use their best
efforts to comply with all federal and state laws and regulations and Nasdaq and
stock exchange listing requirements applicable to any purchase and sale of
shares of New Securities under this Section 8.1. The issuance of such shares
shall be subject to compliance with applicable laws and regulations and
requirements of Nasdaq and any applicable stock exchange.
(iii) Except as otherwise specifically provided herein, upon
receipt of the applicable Purchaser's Notice by the Company, the Purchaser and
the Company each shall be obligated, subject to the other terms and conditions
of this Agreement, to consummate the purchase and sale contemplated by this
Section 8.1 and shall use their best efforts to secure any approvals required in
connection therewith.
(iv) Any Shares acquired by the Purchaser hereunder and all of
Purchaser's rights to maintain, shall be subject to all restrictions and
obligations of the Purchaser set forth elsewhere in this Agreement including,
but not limited to, Section 7.1 of this Agreement.
8.2 The Purchaser's Board Representation Rights.
(a) At the Company's first Board of Directors meeting following
the Closing, the Board of Directors of the Company shall elect to the Company's
Board of Directors a person designated by the Purchaser who is either a senior
business executive of the Purchaser or has business experience comparable to a
senior business executive (the "Purchaser Director"); provided however, that the
election of the Purchase Director to the Company's Board of Directors must occur
no later than January 31,2000.
(b) So long as the Purchaser beneficially owns all Common Shares
purchased by the Purchaser at the Closing and, if it should occur, at the Second
Closing, the Company shall include in the slate of nominees recommended by the
Company's Board of Directors or management to stockholders for election as
directors at the annual meeting of stockholders of the Company, anticipated to
be held in May 2000. The Company's Board of Directors and management shall vote
-21-
<PAGE>
all shares for which the Company's management or Board of Directors hold proxies
or is otherwise entitled to vote in favor of the Purchaser Director. In the
event that the Purchaser Director shall cease to serve as a director for any
reason, the vacancy resulting thereby shall be filled by a designee of the
Purchaser reasonably acceptable to the Company.
8.3 The Purchaser's Registration Rights. Effective upon the earlier to
occur of (i) November 30, 2004, (ii) any termination by the Purchaser (not the
Company) of the Marketing and Distribution Agreement pursuant to Section 10
thereof, or (iii) following the acquisition by a person or 13D Group (which is
not and does not include the Purchaser or any affiliate of the Purchaser) of
more than 20% of the Total Current Voting Power of the Company, the Purchaser
shall have the following registration rights:
(a) Company Registration.
(i) Notice of the Purchaser. If at any time or from time to
time, the Company shall determine to register any Company Common Stock, for its
own account or for the account of others (other than the Purchaser), other than
a registration relating solely to employee benefit plans or a registration
relating solely to a Commission Rule 145 transaction or a registration on any
registration form which does not include substantially the same information as
would be required to be included in a registration statement covering the sale
of the Shares, the Company will:
1) Promptly give to the Purchaser written notice thereof
(which shall include a list of the jurisdictions in which the Company intends to
attempt to qualify such securities under the applicable blue sky or other state
securities laws); and
2) include in such registration (and any related
qualification under blue sky laws or other compliance), and in any underwriting
involved therein, all the Shares specified in a written request or requests,
made within ten (10) days after receipt of such written notice from the Company,
by the Purchaser.
(ii) Underwriting. If the registration of which the Company
gives notice is for a registered public offering involving an underwriting, the
Company shall so advise the Purchaser as a part of the written notice given
pursuant to Section 8.3(a)(i). In such event the right of the Purchaser to
registration pursuant to Section 8.3(a) shall be conditioned upon the
Purchaser's participation in such underwriting and the inclusion of the
Purchaser's Shares in the underwriting to the extent provided herein. If the
Purchaser proposes to distribute its Shares through such underwriting, it shall
(together with the Company) enter into an underwriting agreement in customary
form with the underwriter or underwriters selected for such underwriting by the
Company. Notwithstanding any other provision of this Section 8.3, if the Company
and the underwriter determine that marketing factors require a limitation of the
number of shares to be underwritten, the Company and the underwriter may limit
the number of Shares to be included in the registration and underwriting to any
amount that the Company and the underwriter may determine. The Company shall so
advise the Purchaser, and the number of Shares that may be included in the
registration and
-22-
<PAGE>
underwriting shall be allocated to the Purchaser as the Company and underwriter
may determine at the time of filing the registration statement.
No Shares excluded from the underwriting by reason of
the marketing limitation shall be included in such registration. If the
Purchaser disapproves of the terms of any such underwriting, it may elect to
withdraw therefrom by written notice to the Company and the underwriter.
(b) Form S-3. In addition to the rights contained in the foregoing
provision of this Section 8.3(a), the Purchaser shall have the right to request
up to two (2) registrations on Form S-3 under this Section 8.3(b) (such requests
shall be in a writing signed by the Purchaser and shall state the number of
Shares to be disposed of and the intended method of disposition of such Shares
by the Purchaser), provided that the Company shall not be required to effect a
registration pursuant to this Section 8.3(b) unless the Purchaser proposes to
dispose of Shares which the Purchaser reasonably anticipates will have an
aggregate disposition price (before deduction of underwriting discounts and
expenses of sale) of at least five hundred thousand dollars ($500,000), provided
further that the Company shall not be required to effect a registration pursuant
to this Section 8.3(b) if at the time of the request for a registration on Form
S-3 the Company in good faith gives notice within thirty (30) days of such
request that it is engaged or has fixed plans to engage within sixty (60) days
of the time of the request in a firmly underwritten registered public offering
(but such notice may not be given more than once in any six (6) month period),
and provided further that the Company shall not be required to effect more than
one registration pursuant to this Section 8.3(b) in any twelve (12) month
period.
(c) Expenses of Registration. All Registration Expenses incurred in
connection with any registration pursuant to Section 8.3(a) or Section 8.3(b)
shall be borne by the Company. "Registration Expenses" shall mean all expenses
incurred by the Company in complying with Sections 8.3(a) and 8.3(b) hereof
including, without limitation, all registration and filing fees, printing
expenses, fees and disbursements of counsel for the Company, blue sky fees and
expenses, and the expense of any special audits incident to or required by any
such registration (but excluding the compensation of regular employees of the
Company which shall be paid in any event by the Company and Selling Expenses (as
defined hereinafter). All Selling Expenses incurred in connection with any
registrations hereunder, shall be borne by the Purchaser. "Selling Expenses"
shall mean all underwriting discounts and selling commissions applicable to the
sale of the Shares.
(d) Registration Procedures. In the case of each registration,
qualification or compliance effected by the Company pursuant to this Section
8.3, the Company will keep the Purchaser advised in writing as to the initiation
of each registration, qualification and compliance and as to the completion
thereof. At its expense the Company will:
(i) Keep such registration, qualification or compliance
effective for a period of one hundred twenty (120) days or until the Purchaser
has completed the distribution described in the registration statement relating
thereto, whichever first occurs; and
-23-
<PAGE>
(ii) Furnish such number of prospectuses and other documents
incident thereto as the Purchaser from time to time may reasonably request.
(e) Indemnification.
(i) The Company will indemnify the Purchaser, each of its
officers, directors, partners and legal counsel, and each person controlling the
Purchaser within the meaning of the Securities Act, with respect to which
registration, qualification or compliance has been effected pursuant to this
Section 8.3, against all claims, losses, damages and liabilities (or actions in
respect thereof) arising out of or based on (i) any untrue statement (or alleged
untrue statement) of a material fact contained in any prospectus, offering
circular or other similar document (including any related registration
statement, notification or the like) incident to any such registration,
qualification or compliance, or based on any omission (or alleged omission) to
state therein a material fact required to be stated therein or necessary to make
the statements therein not misleading in the light of the circumstances under
which they were made, or (ii) any violation by the Company of any federal, state
or common law rule or regulation applicable to the Company in connection with
any such registration, qualification or compliance, and will reimburse the
Purchaser, each of its officers and directors, and each person controlling the
Purchaser, for any legal and any other expenses reasonably incurred in
connection with investigating or defending any such claim, loss, damage,
liability or action, as incurred, provided that the Company will not be liable
in any such case to the extent that any such claim, loss, damage, liability or
expense arises out of or is based on any untrue statement or omission based upon
written information furnished to the Company by an instrument duly executed by
the Purchaser and stated to be specifically for use therein or furnished by the
Purchaser to the Company in response to a request by the Company stating
specifically that such information will be used by the Company therein.
(ii) The Purchaser will indemnify the Company, each of its
directors and officers, each legal counsel and independent accountant of the
Company, each person who controls the Company within the meaning of the
Securities Act, against all claims, losses, damages and liabilities (or actions
in respect thereof) arising out of or based on any untrue statement (or alleged
untrue statement) of a material fact contained in any such registration
statement, prospectus, offering circular or other similar document, or any
omission (or alleged omission) to state therein a material fact required to be
stated therein or necessary to make the statements therein not misleading in the
light of the circumstances under which they were made, and will reimburse the
Company, such directors, officers, persons, or control persons for any legal or
any other expenses reasonably incurred in connection with investigating or
defending any such claim, loss, damage, liability or action, as incurred, in
each case to the extent, but only to the extent, that such untrue statement (or
alleged untrue statement) or omission (or alleged omission) is made in such
registration statement, prospectus, offering circular or other document in
reliance upon and in conformity with written information furnished to the
Company by an instrument duly executed by the Purchaser and stated to be
specifically for use therein or furnished by the Purchaser to the Company in
response to a request by the Company stating specifically that such information
will be used by the Company therein.
-24-
<PAGE>
(iii) Each party entitled to indemnification under this
Section 8.3(e) (the "Indemnified Party") shall give notice to the party required
to provide indemnification (the "Indemnifying Party") promptly after such
Indemnified Party has received written notice of any claim as to which indemnity
may be sought, and shall permit the Indemnifying Party to assume the defense of
any such claim or any litigation resulting therefrom, provided that counsel for
the Indemnifying Party, who shall conduct the defense of such claim or
litigation, shall be approved by the Indemnified Party (whose approval shall not
unreasonably be withheld). The Indemnified Party may participate in such defense
at such party's expense; provided, however, that the Indemnifying Party shall
bear the expense of such defense of the Indemnified Party if representation of
both parties by the same counsel would be inappropriate due to actual or
potential conflicts of interest. The failure of any Indemnified Party to give
notice within a reasonable period of time as provided herein shall relieve the
Indemnifying Party of its obligations under this Section 8.3(e) only to the
extent that such failure to give notice shall materially adversely prejudice the
Indemnifying Party in the defense of any such claim or any such litigation. No
Indemnifying Party, in the defense of any such claim or litigation, shall,
except with the consent of each Indemnified Party, consent to entry of any
judgment or enter into any settlement which does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such Indemnified Party
of a release from all liability in respect to such claim or litigation.
(iv) Notwithstanding the foregoing, to the extent that the
provisions on indemnification contained in the underwriting agreement entered
into in connection with the underwritten public offering are in conflict with
the foregoing provisions, the provisions in the underwriting agreement shall
control.
(v) The obligations of the Company and Purchaser under this
Section 8.3 shall survive the completion of any offering of the Shares in a
registration statement under this Section 8.3, and otherwise.
(f) Information by the Purchaser. The Purchaser shall furnish to the
Company such information regarding the Purchaser and the distribution proposed
by the Purchaser as the Company may request in writing and as shall be required
in connection with any registration, qualification or compliance referred to in
this Section 8.
(g) Delay of Registration. The Purchaser shall not have any right to
obtain or seek an injunction restraining or otherwise delaying any such
registration as the result of any controversy that might arise with respect to
the interpretation or implementation of this Section 8.3.
(h) Termination of Registration Rights. All rights and duties
provided for in this Section 8.3 shall terminate on the earlier of (i) the date
five (5) years from the effective date of the registration rights provided in
this Section 8.3, or (ii) the date that the Purchaser is able to dispose of all
of the Shares in one three-month period pursuant to Rule 144.
8.4 The Purchaser's Right to Increase its Ownership Interest.
-25-
<PAGE>
(a) Number of Shares. At any time during the period commencing on
the date the Company receives premarket approval from the FDA for the Company's
Vibrant P and Vibrant D soundbridges and ending on the earlier of (i) November
30, 2004 or (ii) any termination by the Purchaser of the Marketing and
Distribution Agreement pursuant to Section 10 thereof, the Purchaser shall have
the right to purchase from the Company, and the Company shall issue and sell to
the Purchaser up to that number of shares of Company Common Stock ("Additional
Shares") which would, taking into account all Shares Beneficially Owned by the
Purchaser immediately after the acquisition of the Additional Shares, give the
Purchaser 20% of the Total Current Voting Power of the Company immediately
following the acquisition of the Additional Shares.
(b) Purchase Price. The purchase price for the Additional Shares
shall be equal to the average of the closing sales price of the Company Common
Stock as reported by Nasdaq for the forty (40) trading days immediately
preceding the receipt by the Company of written notice from the Purchaser of its
intent to exercise its rights pursuant to this Section 8.4 (an "Exercise
Notice"). In the event of any stock split or stock dividend occurring during the
period from the fortieth (40th) trading day prior to the receipt by the Company
of the Exercise Notice to the date of the closing of the purchase of the
Additional Shares, the purchase price shall be adjusted by a factor equal to the
inverse of the ratio of the stock split or stock dividend.
(c) Compliance. The issuance of the Additional Shares pursuant to
this Section 8.4 shall be subject to compliance with all applicable laws,
including the HSR Act, and the requirements of Nasdaq and any applicable stock
exchange.
(d) Closing. The closing of the purchase of Additional Shares shall
take place at the location and on the date stated in the Exercise Notice, which
in any case shall not be less than five business days after the date of the
Exercise Notice (the "Additional Closing Date"). At the closing, the Purchaser
shall pay the purchase price by wire transfer or certified check, and the
Company shall deliver a certificate representing the Additional Shares and an
opinion from Wilson Sonsini Goodrich & Rosati, counsel to the Company,
substantially in the form attached as Exhibit A, dated as of the Additional
Closing Date.
Section 9
Indemnification
9.1 Survival of Representations and Warranties. Notwithstanding any right
of Purchaser fully to investigate the affairs of the Company and notwithstanding
any knowledge of facts determined or determinable by Purchaser pursuant to such
investigation or right of investigation, the Purchaser has the right to rely
fully upon the representations, warranties, covenants and agreements of the
Company contained in this Agreement. All representations and warranties here
shall survive the execution and delivery of this Agreement after the Closing and
all covenants and agreements shall survive until performed or waived.
-26-
<PAGE>
9.2 Obligation to Indemnify.
(a) The Company agrees to indemnify, defend and hold harmless the
Purchaser and its Affiliates (and the directors, officers, employees, successors
and assigns of each of them) from and against all claims, actions, suits,
losses, liabilities, damages, deficiencies, judgments, settlements, costs of
investigation or other expenses (including but not limited to interest,
penalties and reasonable attorneys' fees and disbursements incurred in
connection with enforcing this indemnification or otherwise in connection with
any of the foregoing) (collectively, the "Losses") based upon, arising out of or
otherwise in respect of any inaccuracy in or any breach of any representation or
warranty or covenant of the Company contained in this Agreement.
(b) The Purchaser agrees to indemnify, defend and hold harmless the
Company and its Affiliates (and the directors, officers, employees, successors
and assigns of each of them) from and against all Losses based upon, arising out
of or otherwise in respect of any inaccuracy in or any breach of any
representation or warranty or covenant of the Purchaser contained in this
Agreement.
9.3 Notice and Opportunity to Defend.
(a) In the event that any person entitled to indemnification
hereunder shall sustain or incur any Losses in respect of which indemnification
may be sought by such person pursuant to Section 9.2, the person seeking such
indemnification (the "Indemnitee") shall assert a claim for indemnification by
giving prompt written notice thereof (a "Claims Notice") which shall describe in
reasonable detail the facts and circumstances upon which the asserted claim for
indemnification is based, to the party providing indemnification (the
"Indemnitor") and shall thereafter keep the Indemnitor reasonably informed with
respect thereto; provided that failure of the Indemnitee to give the Indemnitor
prompt notice as provided herein shall not relieve the Indemnitor of any of its
obligations hereunder, except to the extent that the Indemnitor is materially
prejudiced by such failure. In case any claim, action, suit, hearing or other
proceeding (a "Claim") is brought against any Indemnitee, the Indemnitor shall
have the right to assume, conduct and control the defense, compromise or
settlement thereof, by written notice to the Indemnitee of its intention to do
so within ten (10) days after receipt of the Claims Notice, with counsel
reasonably satisfactory to the Indemnitee, at the Indemnitor's own expense, and
thereupon to prosecute in the name and on behalf of the Indemnitee any available
cross-claims, counterclaims or third-party claims arising with respect to the
Claim. If the Indemnitor shall assume the defense of such Claim, it shall not
settle such Claim unless such settlement includes as an unconditional term
thereof the giving by the claimant or the plaintiff of a release of the
Indemnitee, satisfactory to the Indemnitee, from all liability with respect to
such Claim, nor shall the Indemnitor settle such Claim without the written
consent of the Indemnitee. As long as the Indemnitor is contesting any such
Claim in good faith and on a timely basis, the Indemnitee shall not pay or
settle any such Claim. Notwithstanding the assumption by the Indemnitor of the
defense of any Claim as provided in this Section 9.3(a) and without limiting the
Indemnitor's right to assume, conduct and control the defense, compromise or
settlement thereof, the Indemnitee shall be permitted to join in the defense of
such Claim and to employ counsel at its own expense, so long as such joining
does not interfere with the Indemnitor's right to conduct and control such
matter.
-27-
<PAGE>
(b) If the Indemnitor shall fail to notify the Indemnitee of its
desire to assume the defense of any such Claim within the prescribed ten (10)
day period set forth in Section 9.3(a), or shall notify the Indemnitee that it
will not assume the defense of any such Claim, or if the Indemnitee shall have
defenses available to it which conflict with or are different than the defenses
of the Indemnitor, then the Indemnitee may assume the defense of any such Claim
at the Indemnitor's expense, in which event it may do so in such manner as it
may deem appropriate, and the Indemnitor shall be bound by any determinations
made in any litigation or other proceeding with respect to such Claim or any
settlement thereof effected by the Indemnitee.
Section 10
Miscellaneous
10.1 Waivers and Amendments. Neither this Agreement nor any provisions
hereof shall be waived, modified, changed or discharged or terminated except by
an instrument in writing signed by the party against whom any waiver,
modification, change, discharge or termination is sought.
10.2 Governing Law. This Agreement shall be governed in all respects by
and construed in accordance with the laws of the State of New York without any
regard to conflicts of laws principles.
10.3 Consent to Jurisdiction. Subject to the provisions of Section 10.4,
each of the Company and Purchaser hereby agrees to submit to the exclusive
jurisdiction of the U.S. Federal courts in the Southern District of the State of
New York, and consents that service of process with respect to all such courts
may be made by registered mail to such Person at the address of such Person set
forth in Section 10.9 below with respect to any disputes arising out of this
Agreement.
10.4 Release of Siemens Audiologische Technik and Siemens
Aktiengesellschaft. If the Purchaser assigns its rights and obligations under
this Agreement pursuant to Section 10.7, Siemens Corporation shall be subject to
Section 10.3 and so long as Siemens Corporation is subject to the jurisdiction
of the Federal, state or local courts of the United States with respect to
claims or disputes relating to this Agreement and the transactions contemplated
hereby, the Company for itself and its Affiliates hereby irrevocably and
unconditionally waive and release all rights and claims that it or any of them
may thereafter have that Purchaser, its parent company Siemens
Aktiengesellschaft, Berlin and Munich, a German corporation, is or has been at
any time subject to the jurisdiction of the Federal, state or local courts of
the United States arising out of claims or disputes relating to this Agreement,
and the transactions contemplated hereby.
10.5 Waiver of Jury Trial; Trial Costs. Each of the Company, for itself
and its Affiliates, and Purchaser hereby irrevocably waives all right to trial
by jury in any action, proceeding or counterclaim (whether based on contract,
tort or otherwise) arising out of or relating to the actions of the Company and
Purchaser or its Affiliates pursuant to this Agreement in the negotiation,
-28-
<PAGE>
administration, performance or enforcement thereof. The party in whose favor a
final judgment is rendered shall be entitled to reasonable costs and reasonable
attorneys' fees.
10.6 Survival. The representations, warranties, covenants and agreements
made in this Agreement shall survive any investigation made by the Company or
the Purchaser, the Closing and the Second Closing.
10.7 Successors and Assigns. The provisions hereof shall inure to the
benefit of, and be binding upon, the successors, assigns, heirs, executors and
administrators of the parties to this Agreement. Purchaser may assign this
Agreement to any of its wholly-owned subsidiaries or Affiliates who have the
economic resources to fulfill Purchaser's obligations under this Agreement and
agree in writing to be bound by the terms hereof. Purchaser agrees to notify the
Company immediately upon the execution of any such assignment. Purchaser further
agrees to fulfill any obligations under this Agreement that any such assignee
fails to fulfill.
10.8 Entire Agreement. This Agreement, including all exhibits, hereto
constitutes the full and entire understanding and agreement between the parties
with regard to the subjects hereof and thereof.
10.9 Notices, etc. All notices and other communications required or
permitted under this Agreement shall be effective upon receipt and shall be in
writing and may be delivered in person, by telecopy, overnight delivery service
or registered or certified United States mail, addressed:
If to the Company: Alfred G. Merriweather
Vice President Finance and Chief Financial
Officer
2331 Zanker Road
San Jose, CA 95131
Facsimile: (408) 232-0720
With a courtesy copy to: Issac J. Vaughn
Wilson Sonsini Goodrich & Rosati
650 Page Mill Rd.
Palo Alto, CA 94304
Facsimile: (650) 493-9811
If to the Purchaser to: Mr. Hans Mehl
Siemens Audiologische Technik GmbH
Gebbertstrasse 125
D-91058 Erlangen Germany
Facsimile: 011-49-9131-308-204
with a courtesy copy to: Kenneth R. Meyers, Esq.
Siemens Corporation
1301 Avenue of the Americas
New York, NY 10014
-29-
<PAGE>
Facsimile (212) 258-4945
All notices and other communications shall be effective upon the earlier of
actual receipt thereof by the person to whom notice is directed or (i) in the
case of notices and communications sent by personal delivery or telecopy, one
business day after such notice or communication arrives at the applicable
address or was successfully sent to the applicable telecopy number, (ii) in the
case of notices and communications sent by overnight delivery service, at noon
(local time) on the second business day following the day such notice or
communication was sent, and (iii) in the case of notices and communications sent
by United States mail, seven days after such notice or communication shall have
been deposited in the United States mail.
10.10 Severability of this Agreement. If any provision of this Agreement
shall be judicially determined to be invalid, illegal or unenforceable, the
validity, legality and enforceability of the remaining provisions shall not in
any way be affected or impaired thereby.
10.11 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be an original, but all of which together
shall constitute one instrument.
10.12 Further Assurances. Each party to this Agreement shall do and
perform or cause to be done and performed all such further acts and things and
shall execute and deliver all such other agreements, certificates, instruments
and documents as the other party hereto may reasonably request in order to carry
out the intent and accomplish the purposes of this Agreement and the
consummation of the transactions contemplated hereby.
10.13 Expenses. Each of the Company and the Purchaser shall bear its own
expenses incurred on its behalf with respect to this Agreement and the
transactions contemplated hereby.
10.14 Currency. All references to "dollars" or "$" in this Agreement shall
be deemed to refer to United States dollars.
-30-
<PAGE>
The foregoing agreement is hereby executed as of the date first above
written.
"COMPANY"
SYMPHONIX DEVICES, INC.
a Delaware corporation
By: /s/ Kirk Davis
__________________________________
Title: President and Chief Executive
Officer
"PURCHASER"
SIEMENS AUDIOLOGISCHE TECHNIK GmbH
By: /s/ G. Steinhardt
__________________________
Title: Vice President
Medical Systems Group
By: /s/ W. Mueller - Huschke
__________________________
Title: Corporate Legal Counsel
-31-
<PAGE>
EXHIBIT A
FORM OF OPINION OF WILSON SONSINI GOODRICH & ROSATI
<PAGE>
November ___, 1999
Siemens Audiologische Technik GmbH
Gebbertstrasse 125
D-91058 Erlangen Germany
Ladies and Gentlemen:
Reference is made to the Common Stock Purchase Agreement, dated as of
November ___, 1999 (the "Agreement"), complete with all listed exhibits thereto,
by and among Symphonix Devices, Inc., a Delaware corporation (the "Company") and
Siemens Audiologische Technik GmbH (the "Purchaser"), which provides for the
issuance by the Company to the Purchaser of shares of Common Stock of the
Company (the "Shares"). This opinion is rendered to you pursuant to Section
5.1(d) of the Agreement, and all terms used herein have the meanings defined for
them in the Agreement unless otherwise defined herein.
We have acted as counsel for the Company in connection with the
negotiation of the Agreement and the issuance of the Shares. As such counsel, we
have made such legal and factual examinations and inquiries as we have deemed
advisable or necessary for the purpose of rendering this opinion. In addition,
we have examined, among other things, originals or copies of such corporate
records of the Company, certificates of public officials and such other
documents and questions of law that we consider necessary or advisable for the
purpose of rendering this opinion. In such examination we have assumed the
genuineness of all signatures on original documents, the authenticity of all
documents submitted to us as originals, the conformity to original documents of
all copies submitted to us as copies thereof, the legal capacity of natural
persons, and the due execution and delivery of all documents (except as to due
execution and delivery by the Company) where due execution and delivery are a
prerequisite to the effectiveness thereof.
As used in this opinion, the expression "to our knowledge" with reference
to matters of fact means that, after an examination of documents made available
to us by the Company, and after inquiries of officers of the Company, but
without any further independent factual investigation, we find no reason to
believe that the opinions expressed herein are factually incorrect. Further, the
expression "to our knowledge" with reference to matters of fact refers to the
current actual knowledge of the attorneys of this firm who have worked on
matters for the Company solely in connection with the Agreement and the
transactions contemplated thereby. Except to the extent expressly set forth
herein or as we otherwise believe to be necessary to our opinion, we have not
undertaken any independent investigation to determine the existence or absence
of any fact, and no inference as to our knowledge of the existence or absence of
any fact should be drawn from our representation of the Company or the rendering
of the opinion set forth below.
For purposes of this opinion, we are assuming that you have all requisite
power and authority, and have taken any and all necessary corporate or
partnership action, to execute and deliver the
-2-
<PAGE>
Agreement, and we are assuming that the representations and warranties made by
the Purchaser in the Agreement and pursuant thereto are true and correct. We are
also assuming that the Purchaser has acquired the Shares, for value, in good
faith and without notice of any adverse claims within the meaning of the
California Uniform Commercial Code.
The opinions hereinafter expressed are subject to the following
qualifications:
a) We express no opinion as to the effect of applicable bankruptcy,
insolvency, reorganization, moratorium or other similar federal or state laws
affecting the rights of creditors and secured parties, including, without
limitation, federal, state or other laws regarding fraudulent transfers;
b) We express no opinion as to the effect or availability of rules
of law governing specific performance, injunctive relief or other equitable
remedies (regardless of whether any such remedy is considered in a proceeding at
law or in equity);
c) We express no opinion as to compliance with applicable anti-fraud
provisions of federal or state securities laws;
d) We express no opinion as to the enforceability of the
indemnification provisions of Section 9 of the Agreement to the extent the
provisions thereof may be subject to limitations of public policy and the effect
of applicable statutes and judicial decisions; and
e) We are members of the Bar of the State of California and, we are
not expressing any opinion as to any matter relating to the laws of any
jurisdiction other than the federal laws of the United States of America and the
laws of the State of California and the General Corporation Law of the State of
Delaware. To the extent this opinion addresses applicable securities laws of
states other than the State of California, we have not retained or relied upon
the opinions of counsel admitted to the bars of such states, but rather have
relied upon compilations of the securities laws of such states contained in
reporting services currently available to us.
Based upon and subject to the foregoing, and except as set forth in the
Agreement, we advise you that in our opinion:
1. The Company is a corporation duly organized and validly existing under,
and by virtue of, the laws of the State of Delaware and is in good standing
under such laws. The Company has requisite corporate power to own and operate
its properties and assets, and to conduct its business. The Company is qualified
to do business as a foreign corporation in each jurisdiction in which the
failure to be so qualified would have a material adverse effect on the Company's
business, financial condition or results of operations.
2. The Company has all requisite legal and corporate power to execute and
deliver the Agreement, to sell and issue the Shares under the Agreement, and to
carry out and perform its obligations under the terms of the Agreement.
-3-
<PAGE>
3. As of the date hereof, the authorized capital stock of the Company
consists of 50,000,000 shares of Common Stock and 5,000,000 shares of Preferred
Stock. The Shares issued under the Agreement are validly issued, fully paid and
nonassessable and free of any liens, encumbrances and preemptive or similar
rights contained in the Restated Certificate of Incorporation or Bylaws of the
Company, or, to our knowledge, in any agreement identified to us as material by
which the Company is bound, except as provided or referred to in the Agreement;
provided, however, that the Shares, may be subject to restrictions on transfer
under state and/or federal securities laws as set forth in the Agreement. To our
knowledge, except for rights described in the Agreement, the SEC Documents, the
Restated Certificate of Incorporation or the Bylaws, there are no other options,
warrants, conversion privileges or other rights currently outstanding to
purchase or otherwise acquire any authorized but unissued shares of capital
stock or other securities of the Company, or any other agreements to issue any
such securities or rights, pursuant to any written agreement identified to us as
material by which the Company is bound.
4. All corporate action on the part of the Company, its directors and
stockholders necessary for the authorization, execution and delivery of the
Agreement by the Company, the authorization, sale, issuance and delivery of the
Shares, and the performance of the Company's obligations under the Agreement has
been taken. The Agreement has been duly and validly executed and delivered by
the Company and constitutes a valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms.
5. The execution, delivery and performance of and compliance with the
terms of the Agreement and the issuance of the Shares, do not violate any
provision of the Restated Certificate of Incorporation or Bylaws, or, to our
knowledge, any provision of any applicable federal or state law, rule or
regulation. To our knowledge, the execution, delivery and performance of and
compliance with the Agreement and the issuance of the Shares, have not resulted
and will not result in any material violation of, or constitute a material
default under, any indenture, mortgage or deed of trust or other agreement,
instrument, court order, judgment or decree binding upon the Company and
identified to us as material.
6. No consent, approval or authorization of or designation, declaration or
filing with any United States governmental authority on the part of the Company
is required in connection with the valid execution and delivery of the
Agreement, or the offer, sale or issuance of the Shares, or the consummation of
any other transaction contemplated thereby, except the filing with the Nasdaq
Stock Market of a notice of listing of additional shares on Form 10b-17.
This opinion is furnished to the Purchaser solely for its benefit in
connection with the purchase of the Shares, and may not be relied upon by any
other person or for any other purpose without our prior written consent.
Very truly yours,
WILSON SONSINI GOODRICH & ROSATI
-4-
<PAGE>
Professional Corporation
-5-
<PAGE>
SYMPHONIX DEVICES, INC.
DISCLOSURE SCHEDULE
This disclosure schedule (the "Disclosure Schedule"), which consists of
this cover page and all of the accompanying pages and attachments, is made and
given by the Company to the Purchaser in connection with the execution and
delivery of that certain Common Stock Purchase Agreement dated as of November
___, 1999 by and between the Purchaser and the Company (the "Agreement"). Any
terms defined in the Agreement shall have the same meaning when used in the
Disclosure Schedule unless the context otherwise requires.
Any reference to or listing, description, disclosure or other inclusion of
any item or other matter in the Disclosure Schedule shall not be construed to
mean that such item or other matter is material or that such item or other
matter is required to be referred to, listed, described, disclosed or otherwise
included in the Disclosure Schedule. Any reference to or listing, description,
disclosure or other inclusion of any agreement or document in the Disclosure
Schedule shall not be construed to mean that such agreement or document is
currently in effect or that there are any obligations remaining to be performed
or any exercisable rights under such agreement or document.
The Disclosure Schedule and the information, descriptions and disclosures
included in the Disclosure Schedule are intended to qualify and limit the
corresponding specifically identified representations, warranties and covenants
of the Company contained in the Agreement and shall not be deemed to expand in
any way the scope or effect of any of such representations, warranties or
covenants.
The headings contained in the Disclosure Schedule are included for
convenience only and are not intended to limit the effect of the disclosures
included in the Disclosure Schedule nor to expand the scope of the information
required to be disclosed in the Disclosure Schedule.
3.1 Organization and Standing.
The Company currently has the following wholly owned subsidiaries:
Symphonix Devices, GmbH (Germany)
Symphonix Devices, Ltd. (United Kingdom)
Symphonix Devices, AG (Switzerland)
VibRx, Inc. (California)
3.8 Intellectual Property.
None.
<PAGE>
3.9 Authorized Capital Stock.
(a) Lighthouse Capital Partners holds warrants to purchase 33,611
shares of the Common Stock of the Company with a weighted average exercise price
of $1.60 per share.
(b) The following table sets forth the holders of 5% or more of the
Company's Common Stock as of September 30, 1999:
--------------------------------------------------------------------
Name Number of Shares
--------------------------------------------------------------------
Sierra Ventures IV 1,850,892
Sierra Ventures IV International 74,116
3000 Sand Hill Road
Building 4, Suite 210
Menlo Park, CA 94025
--------------------------------------------------------------------
Mayfield VII 1,567,446
Mayfield Associates Fund II 82,499
Mayfield VII Management Partners 32,704
2800 Sand Hill Road, 2nd Floor
Menlo Park, CA 94025
--------------------------------------------------------------------
Harry S. Robbins 1,276,184
Symphonix Devices, Inc.
2331 Zanker Road
San Jose, CA 95131
--------------------------------------------------------------------
Coral Partners 1,099,965
60 South Sixth Street, Suite 3510
Minneapolis, MN 55402
--------------------------------------------------------------------
-2-
<PAGE>
3.11 Compliance With Other Instruments.
--------------------------------------------------------------------
Distributor Territory Termination
--------------------------------------------------------------------
Gaes SA Spain, Portugal 1/1/00 - has
rolled over to new
term with 90 day
notice period
--------------------------------------------------------------------
Biomedical Technology SRL Italy 4/1/01
--------------------------------------------------------------------
Newmedic SA Belgium, 1/1/00 -
Netherlands, termination notice
Luxembourg given
--------------------------------------------------------------------
Newmedic International SA Lebanon, Syria, 7/1/01
Jordan, Saudi
Arabia, Egypt,
United Arab
Emirates, Kuwait,
Algeria, Morocco,
Tunisia
--------------------------------------------------------------------
Danaflex Denmark 4/1/00
--------------------------------------------------------------------
Biocord SA Sweden 4/1/00
--------------------------------------------------------------------
Med El Latin America Argentina, Brazil, 10/2/01 with
Colombia, Peru, automatic renewal
Bolivia, Paraguay, if quotas are
Venezuela, Ecuador, met. Contract is
Uruguay currently being
restructured to
reduce the
territory and
convert to annual
renewals without
regard to quotas
--------------------------------------------------------------------
--------------------------------------------------------------------
-3-
EXHIBIT 7.2
Erlangen, November 2, 1999
MARKETING and DISTRIBUTION AGREEMENT
between
SYMPHONIX Devices, Inc.
2331 Zanker Road, San Jose, CA 95131.1109, USA
(hereinafter referred to as "SYMPHONIX")
and
SIEMENS Audiologische Technik GmbH,
Gebbertstr. 125, Erlangen, Germany
(hereinafter referred to as "SIEMENS")
Collectively referred to as "The Parties"
<PAGE>
WHEREAS SIEMENS is a designer, manufacturer and distributor of hearing
instruments and components for hearing instruments, including integrated
circuits and hybrids for hearing instruments; and
WHEREAS SYMPHONIX is a designer, manufacturer and distributor of
semi-implantable and totally implantable middle ear hearing devices; and
WHEREAS SIEMENS and SYMPHONIX believe that it will be in both of their best
interests to establish a long-term cooperative relationship in connection with
the global positioning of SIEMENS PRODUCTS and SYMPHONIX PRODUCTS as providing a
single continuum of hearing care for the hearing impaired; and
WHEREAS SIEMENS and SYMPHONIX believe that it will be in both of their best
interests to establish, based on this global positioning, certain joint
marketing programs in certain markets and formal distribution agreements for
SYMPHONIX PRODUCTS in certain markets.
DEFINITIONS
"SYMPHONIX PRODUCTS" are defined as all current and future semi-implantable and
totally implantable middle ear devices designed and / or manufactured by
SYMPHONIX. The current SYMPHONIX PRODUCTS are listed in Annex 1. Future
SYMPHONIX PRODUCTS will be included as soon as practical after they become
available.
"SIEMENS PRODUCTS" are defined as all current and future hearing instruments
designed and / or manufactured by SIEMENS.
"TERRITORY" is defined as the countries listed in Annex 2.
1.
2
<PAGE>
Global Marketing Alliance
SIEMENS and SYMPHONIX shall use their best efforts to jointly promote SIEMENS
PRODUCTS and SYMPHONIX PRODUCTS in the global market. SYMPHONIX PRODUCTS shall
be positioned as superior, technologically advanced hearing care solutions that
address unmet needs of hearing impaired people who are dissatisfied with hearing
instruments and therefor are candidates for semi-implantable or totally
implantable hearing devices. SIEMENS PRODUCTS shall be positioned as superior,
technologically advanced hearing instruments. Together, SIEMENS PRODUCTS and
SYMPHONIX PRODUCTS will be positioned as providing a single continuum of care
for the hearing impaired. This joint positioning by SIEMENS and SYMPHONIX will
be exclusive, as to hearing instruments and semi-implantable and totally
implantable hearing devices.
2. Marketing Cooperation
The Parties agree that they will conduct cooperative marketing programs such as
the following:
(i) joint multimedia programs, including educational programs and workshops
aimed at increasing awareness of hearing health care and the benefits of
the SYMPHONIX PRODUCTS among dissatisfied hearing instrument users,
audiologists and hearing instrument dispensers;
(ii) joint attendance at workshops and scientific conferences and sponsorship
of satellite meetings;
(iii) joint attendance at medical / audiological conferences;
(iv) joint sponsorship of educational forums aimed at hearing impaired
individuals;
(v) joint market research studies;
(vi) joint creation of patient
support groups; and
(vii) joint development of a patient data base that produces
cross-referral of patients.
The Parties agree that they will develop specific programs designed to actively
involve hearing instrument dispensers in the promotion of the SYMPHONIX
PRODUCTS. Such programs will be designed to provide incentives to achieve
referral of potential patients to clinical implanting sites. Such programs may
include sale by the hearing instrument dispenser of the external audio processor
(external part of the semi-implantable hearing device), as well as referral fees
and fitting fees.
3
<PAGE>
The Parties intend that these programs will be initiated in the TERRITORY, i. e.
during Q 4 of calendar 1999 in France, during Q 1 of calendar 2000 in Spain,
Germany and UK, and as soon as practical in the other countries of the
TERRITORY. The Parties intend that such programs will be fully implemented in
the United States of America and Canada immediately after initiation of
commercial sales. In all other countries such programs will be implemented if
reasonably possible to do so. Any claims regarding The Parties' respective
products shall be subject to approval by SYMPHONIX for SYMPHONIX PRODUCTS and by
SIEMENS for SIEMENS PRODUCTS.
3. Distribution
SIEMENS is hereby appointed to be the exclusive distributor of SYMPHONIX
PRODUCTS in the TERRITORY, subject to the provisions of Section 4.
The Parties will continually monitor the potential distribution of SYMPHONIX
PRODUCTS in countries not currently included in the TERRITORY. However, it is
expressly agreed that the TERRITORY and the provisions of this paragraph, do not
and will not in the future, include the United States of America and Canada. As
existing SYMPHONIX distribution contracts with third party distributors expire,
or SIEMENS foresees marketing potential for SYMPHONIX PRODUCTS or SYMPHONIX
prepares for distribution of SYMPHONIX PRODUCTS in additional countries,
SYMPHONIX and SIEMENS shall negotiate in good faith the addition of such
countries to the TERRITORY.
The distribution rights include but are not limited to the direct sale to local
distributors, hospitals, ENT doctors, dispensers, health insurance companies and
end users.
4. Existing SYMPHONIX Distribution Agreements with third Parties;
SIEMENS Distributors
The designation of certain countries in Annex 2 as part of the TERRITORY, is
contingent on appropriate termination by SYMPHONIX of existing distribution
agreements. The Parties will cooperate in these cases, subject to the following
paragraph, to ensure as smooth as possible a transition from the existing
distribution agreement to SIEMENS or to a new distribution agreement with the
appropriate third party SIEMENS distributor. The countries covered by this
paragraph are Italy, Spain, Portugal, Denmark and Sweden.
4
<PAGE>
In all cases, where SIEMENS wants to appoint third party distributors in the
TERRITORY for purposes of this AGREEMENT, such appointment is contingent on
SYMPHONIX's explicit prior written approval which shall only be withheld if the
third party distributor distributes products which are directly in competition
to SYMPHONIX PRODUCTS, or if the third party distributor is unable to adequately
market the SYMPHONIX PRODUCTS.
SIEMENS shall ensure that distribution rights granted to its third party
distributors are consistent with the provisions of this Agreement, and do not
exceed the rights granted hereunder to SIEMENS.
5. Scope and Limitation of SIEMENS' Distribution Authority
SIEMENS and SYMPHONIX shall use their reasonable efforts to develop a
comprehensive business plan for distribution of SYMPHONIX PRODUCTS in the
TERRITORY within a period of sixty (60) days after the effective date of this
AGREEMENT. Such business plan will address specific programs and resource
allocations on a country-by-country basis, and will be updated regularly at
least on a yearly basis.
5.1 Introduction Period
The Parties have agreed on principles for such business plan for the
period of the first two (2) years after the effective date as provided in
section 14 ("Introduction Period") as follows:
SIEMENS shall perform in its own name and for its own account all
warehousing, shipping, returns handling, order processing, and invoicing
for SYMPHONIX PRODUCTS;
SYMPHONIX shall provide SIEMENS with adequate quantities of SYMPHONIX
PRODUCTS on a consignment basis and SIEMENS will issue purchase orders
weekly for such SYMPHONIX PRODUCTS, when sold to third party customers
(including third party distributors);
SYMPHONIX shall pay to SIEMENS an amount equal to 5% of the amount
invoiced by SIEMENS (excluding taxes, freight and similar items) to third
party customers and distributors as a handling fee. Such handling fee
will be offset with the purchase price for the corresponding purchase of
SYMPHONIX PRODUCTS by SIEMENS;
5
<PAGE>
SIEMENS shall purchase SYMPHONIX PRODUCTS from SYMPHONIX at prices equal
to SYMPHONIX's list prices, unless SYMPHONIX has explicitly agreed to a
different price for specific transactions;
SIEMENS shall pay all applicable taxes (such as VAT), freight, duty and
similar items due in the TERRITORY and may invoice these as appropriate
to third party distributors and customers;
SIEMENS shall pay all invoices for SYMPHONIX PRODUCTS within thirty (30)
days of the invoice date (net of the 5% handling fee described above);
SYMPHONIX shall retain title to SYMPHONIX PRODUCTS until shipped by
SIEMENS to third party distributors or customers;
SIEMENS will keep accurate records of the consignment inventory
(including by serial numbers), and will make such records available to
SYMPHONIX upon request, including by submission of periodic detailed
inventory reports;
SIEMENS will keep such records, maintain the inventory and process
transactions in such a way as to be in compliance with the applicable
E.U. directives for active implantable medical devices and U.S.
regulations for Class III medical devices;
SIEMENS and SYMPHONIX will agree on a yearly budget with detailed
assignment of cost to be borne by each of the Parties;
SYMPHONIX will be responsible for promotion as well as for clinical and
technical support with surgeons and hospitals, and will bear the cost for
its support personnel in the TERRITORY;
SIEMENS will be responsible for promotion with hearing aid dispensers and
will bear the cost of its hearing instruments sales and support personnel
in the TERRITORY;
SYMPHONIX will render the technical and clinical support to SIEMENS
subsidiaries, third party distributors or any other party interested in
SYMPHONIX PRODUCTS.
6
<PAGE>
5.2 Subsequent Period
Commencing two (2) years from the effective date provided in section 14,
("Subsequent Period") SIEMENS will assume the distribution responsibility
for the SYMPHONIX PRODUCTS under the following principles:
SYMPHONIX PRODUCTS will be purchased by SIEMENS at prices providing
SIEMENS with a discount from SYMPHONIX's price list. Such discount will
be at least 50%. The Parties agree that a discount above 50% for SIEMENS
is possible. However, the purchase price to SIEMENS for SYMPHONIX
PRODUCTS should allow SYMPHONIX at least a 20% manufacturing margin,
fully loaded manufacturing cost considered. The Parties agree that a
manufacturing margin of greater than 20% for SYMPHONIX is possible. The
SIEMENS purchase prices for SYMPHONIX PRODUCTS shall be reviewed on an
annual basis by the Parties;
SIEMENS shall be fully responsible for developing the market in the
TERRITORY, for promoting and selling SYMPHONIX PRODUCTS in the TERRITORY
and for determining its sales prices for SYMPHONIX PRODUCTS. SIEMENS
shall maintain the organization and commit to resources to ensure optimum
sales for SYMPHONIX PRODUCTS under the mutually revised business plan;
From the beginning of the Subsequent Period, i.e. after two (2) years
from the effective date provided in section 14, SIEMENS will assume the
direct sales and support organization of SYMPHONIX with such personnel
becoming employees of SIEMENS, providing that the Parties will have
consulted and mutually agreed upon any increases in staffing levels
during the Introduction Period;
SIEMENS will keep adequate records, maintain the inventory and process
transactions in such a way as to be in compliance with the applicable
E.U. directives for active implantable medical devices and U.S.
regulations for Class III medical devices;
Payment terms will be the same as during the Introduction Period, but
title and risk of loss will pass at the time of shipment by SYMPHONIX,
such shipments being FOB San Jose (INCOTERMS 1990).
7
<PAGE>
5.3 Regulatory Compliance
During both, the Introduction Period and the Subsequent Period, SIEMENS
shall assist SYMPHONIX as follows in complying with regulatory
requirements.
SIEMENS shall refer any complaints regarding SYMPHONIX PRODUCTS to
SYMPHONIX within two (2) working days after they had become known by
SIEMENS, and if a complaint requires follow up actions to be taken,
SIEMENS will provide all required information available at SIEMENS to
SYMPHONIX within one (1) working day.
Pursuant to the United States Federal Drug Administration's ("FDA")
Medical Device Reporting Regulations and E. U. vigilance reporting
requirements, SYMPHONIX may be required to report to the FDA and European
regulatory agencies information that reasonably suggests that a SYMPHONIX
PRODUCT may have caused or contributed to the death or serious injury or
has malfunctioned and that the device would be likely to cause or
contribute to a death or serious injury if the malfunction were to recur.
SIEMENS agrees to supply to SYMPHONIX any such information available at
SIEMENS within forty-eight (48) hours after becoming aware of such
information so that each can comply with governmental reporting
requirements. In the event that a SYMPHONIX PRODUCT is recalled, SIEMENS
shall cooperate with and assist SYMPHONIX in locating, and retrieving if
necessary, recalled SYMPHONIX PRODUCTS from SIEMENS' customers.
SIEMENS shall maintain a system of traceability of the SYMPHONIX PRODUCTS
including the following consignee information in respect of each
SYMPHONIX PRODUCT sold: (1) SYMPHONIX part number, (2) date of receipt of
SYMPHONIX PRODUCT from SYMPHONIX, (3) serial numbers / expiration date,
(4) invoice number under which the unit was shipped to SIEMENS` customer,
(5) date of shipment of unit from SIEMENS` warehouse, (6) name and
address of SIEMENS' consignee (this shall at a minimum be to the level of
the hospital or clinic).
SIEMENS shall use its best efforts to encourage customers to complete and
submit the registration cards included with each SYMPHONIX PRODUCT.
SIEMENS shall allow SYMPHONIX access to audit inventory processing for
conformance to the requirements of EN ISO 9001.
8
<PAGE>
6. Commercial Transactions
Commercial transactions concerning SYMPHONIX PRODUCTS shall be performed by
SIEMENS in its own name and on its own account. However, product liability shall
be borne by SYMPHONIX as per Section 11 of this AGREEMENT.
7. Future Product Development
The Parties enter into this AGREEMENT to establish a long term relationship.
SYMPHONIX shall therefore include SIEMENS and SIEMENS shall include SYMPHONIX as
a participant in its process for the definition and specification of future
products. SYMPHONIX shall make all future SYMPHONIX PRODUCTS available to
SIEMENS for the distribution in the TERRITORY, and such SYMPHONIX PRODUCTS shall
be marketed by SIEMENS as soon as practical after they become available.
8. Products
From time to time Annex 1 shall be modified by adding newly developed SYMPHONIX
PRODUCTS and by deleting obsolete and discontinued SYMPHONIX PRODUCTS. However,
any SYMPHONIX PRODUCT discontinuation will be announced with six (6) months
written notice to SIEMENS. SYMPHONIX will make available to SIEMENS for a period
of at least seven (7) years accessories, spare parts and replacement SYMPHONIX
PRODUCTS of any SYMPHONIX PRODUCT after the effective date of its
discontinuation.
9. Confidentiality
SIEMENS shall not use for its own benefit (except as authorized in this
AGREEMENT) nor make available nor disclose to third parties any technical or
marketing information (e.g., drawings or specifications) or information of a
confidential nature which it may acquire in the course of its cooperation with
SYMPHONIX, and shall also prevent the aforementioned information from being
disclosed to or used by unauthorized parties. SYMPHONIX shall assume the same
obligation with regard to information received from SIEMENS. The above mentioned
obligation does not apply to information which is or will become part of the
public domain or which has been publicly disclosed by the other Party without
breach of a confidentiality obligation. The terms of this provision shall
survive the termination of this AGREEMENT for five (5) years.
9
<PAGE>
10. Default and Extraordinary Termination
In addition to any other termination rights hereunder, each Party shall have the
right to terminate this AGREEMENT and to pursue all remedies available to such
Party, upon the occurrence of any of the following:
(i) a material breach by the other Party of any of any material term or
condition or representation or warranty contained in this AGREEMENT which
such Party fails to cure within thirty (30) days after written notice
thereof;
(ii) the other Party's insolvency, admission of inability to pay its debts as
they become due, filing of a petition for bankruptcy relief or assignment
for the benefit of creditors.
11. Liability
11.1. Indemnification for Infringement of Intellectual Property
SYMPHONIX will defend, at its expense, any action brought against SIEMENS
or SIEMENS' subsidiaries, affiliates, agents, employees or customers to
the extent that it is based on a claim that a SYMPHONIX PRODUCT, when
used in accordance with this Agreement, infringes a patent, trademark or
copyright in the TERRITORY. SYMPHONIX will pay any costs, settlements and
damages finally awarded provided that SIEMENS or SIEMENS' subsidiaries,
affiliates, agents, employees or customers
(i) promptly notifies SYMPHONIX in writing of any claim,
(ii) gives SYMPHONIX sole control of the defense and settlement, and
(iii) provides all reasonable assistance in connection therewith.
SYMPHONIX agrees to keep SIEMENS or SIEMENS' subsidiaries,
affiliates, agents, employees or customers advised of the status of
any claim.
If any SYMPHONIX PRODUCT is finally adjudged to so infringe, or in
SYMPHONIX's opinion such a claim is likely to succeed, SYMPHONIX will, at
its option
(i) procure for SIEMENS the right to continue using the SYMPHONIX
PRODUCT,
(ii) modify or replace the SYMPHONIX PRODUCT so there are no
infringements, or
(iii) refund the price paid including handling charges for logistics
upon return of the SYMPHONIX PRODUCT.
10
<PAGE>
The foregoing states the entire liability of SYMPHONIX and the exclusive
remedy for SIEMENS or SIEMENS' subsidiaries, affiliates, agents,
employees or customers relating to infringement or claims of infringement
of any patent, trademark, copyright, mask work right, trade secret or
other proprietary right by the SYMPHONIX PRODUCT.
11.2. Product Liability Indemnification
SYMPHONIX agrees to defend against and indemnify and hold SIEMENS or
SIEMENS' subsidiaries, affiliates, agents, employees or customers
harmless from product liability claims, losses, damages or expenses
(including costs of defending any proceedings) resulting from the
purchase, sale, storage, transportation or foreseeable use of SYMPHONIX
PRODUCTS, whether brought under theories of express or implied warranty,
negligence or strict liability. This indemnification will not apply to
any SYMPHONIX PRODUCT which, as determined by arbitration or a competent
courts decision, has been
(i) modified without SYMPHONIX's written authorization,
(ii) not used or maintained in compliance with SYMPHONIX's instructions,
(iii) subjected to misuse, improper maintenance, unusual stress or
accident, or
(iv) used or sold after the "Use Before" date specified by SYMPHONIX.
11.3. Conditions to Indemnification Obligations
The indemnification obligations are subject to the following conditions:
(i) the indemnified party gives prompt notice to SYMPHONIX of the
potential liability or claim;
(ii) the indemnified party promptly grants to SYMPHONIX control over its
defence and settlement; and
(iii) the indemnified party, at the indemnifying party's expense,
provides reasonable and timely assistance in defence of the claim.
The indemnified party may, at its option and expense, participate
in the defence and settlement of any claim or liability under this
AGREEMENT; however, if the indemnified party agrees to a settlement
of such claim or liability without the written consent of
SYMPHONIX, SYMPHONIX shall have no obligation to indemnify the
indemnified party in connection with such settlement.
11.4. Product Liability Insurance
SYMPHONIX shall, for the lifetime of the SYMPHONIX PRODUCTS, secure and
maintain a product liability insurance policy providing coverage for
product liability exposure (including negligence and strict liability) to
third parties resulting from defective SYMPHONIX PRODUCTS (such as
design-, manufacture-, instruction defects) supplied by SYMPHONIX to
SIEMENS in the TERRITORY, provided such coverage is available on
commercially reasonable terms. At SIEMENS' request, SYMPHONIX shall
provide SIEMENS a copy of the insurance policy. The Parties shall, during
the term of this agreement, discuss annually the level of insurance
coverage maintained by SYMPHONIX.
11
<PAGE>
11.5. General Indemnity
Unless otherwise provided for this Agreement, either Party will indemnify
and hold the other Party harmless from and against any and all losses,
damages, claims, liabilities, cost and expenses (including reasonable
attorneys` fees) directly resulting from
(i) any gross negligent or intentional breach of this Agreement or any
duty or obligations hereunder, or
(ii) any claims that may be made by reason of any gross negligent
or intentional act or omission of a Party or any of its
subsidiaries, affiliates, agents or employees.
12. WARRANTIES
12.1 SYMPHONIX warrants to SIEMENS that the SYMPHONIX PRODUCTS will on the
date of shipment be free from defects in materials and workmanship, and
will under normal use, starting with the date of implantation, conform in
material respects to the then-current user documentation for a period of
three (3) years for the implanted portion of such SYMPHONIX PRODUCT and
for a period of one (1) year for its external portion, but at least for
the mandatory period under the regulations of the E. U.. This limited
warranty will not apply to any SYMPHONIX PRODUCT which as proved by
SYMPHONIX, has been
(i) modified without SYMPHONIX's written authorization,
(ii) not used or maintained in compliance with SYMPHONIX's instructions,
(iii) subjected to misuse, improper maintenance, unusual stress or
accident, or
(iv) used or sold after the "Use Before" date specified by SYMPHONIX.
This limited warranty extends only to SIEMENS and not to any end user or
customer of SIEMENS. The provisions of this Section 12.1 shall not affect
the statutory rights of any end-user in the TERRITORY.
12.2. SIEMENS shall use its best efforts to ensure with its customers that
procedures for ordering of SYMPHONIX PRODUCT and shipment of stock
precludes having expired SYMPHONIX PRODUCT in stock. Expired SYMPHONIX
PRODUCT must not be sold and is not returnable except for
re-sterilization, at the cost, including freight, of SIEMENS. SYMPHONIX
may by notice in writing require SIEMENS to return any expired SYMPHONIX
PRODUCT to SYMPHONIX for re-sterilization which shall be performed at the
cost including freight of SIEMENS.
13
<PAGE>
12.3 SYMPHONIX shall pass on to SIEMENS good title, free and clear of all
liens and/or encumbrances to SYMPHONIX PRODUCTS delivered as replacement
for non-conforming SYMPHONIX PRODUCTS.
12.4 If SYMPHONIX is unable, within sixty (60) business days of SYMPHONIX'
receipt of defective SYMPHONIX PRODUCTS, to repair or replace
non-conforming SYMPHONIX PRODUCTS, SIEMENS shall be credited the original
purchase price for such SYMPHONIX PRODUCTS. In case of a warranty defect,
which requires a removal from the patients body of defective SYMPHONIX
PRODUCTS as well as a re-implant of repaired/replaced SYMPHONIX PRODUCTS
all direct cost for such surgery, to be paid by SIEMENS shall be borne by
SYMPHONIX, provided SYMPHONIX has approved in advance of the need for
such removal and re-implant.
12.5 SIEMENS shall make no representations to third parties regarding the
performance or functional capabilities or characteristics of the
SYMPHONIX PRODUCTS beyond those stated in SYMPHONIX's then-current
printed Product Specification.
13. Assignment
Neither Party may assign or otherwise transfer this AGREEMENT, or assign any of
its rights or delegate any of its obligations hereunder, without the prior
written consent of the other Party, and any attempted or purported assignment by
either Party without such consent shall be null and void. Notwithstanding the
foregoing, either Party may assign all of its rights and delegate all of its
obligations hereunder in connection with the sale of all or substantially all of
its assets or the reorganization of the assignor, without the prior written
consent of the other Party; provided, however, that any such assignee must
assume all obligations of the assignor under this AGREEMENT to the reasonable
satisfaction of the non-assigning Party.
<PAGE>
14. Duration of AGREEMENT, Ordinary Termination
This AGREEMENT shall become effective upon signature by both Parties of both
this Agreement and the Common Stock Purchase Agreement between the Parties, and
shall remain in force for a period of five (5) years. Notwithstanding the
foregoing, this AGREEMENT shall not terminate before September 30, 2004, except
as provided in Section 10 and 15.
Unless either Party has given twelve (12) months written notice of intent to not
renew this AGREEMENT, this AGREEMENT shall automatically renew for successive
one (1) year periods beyond September 30, 2004. After this date, this AGREEMENT
will be cancelable by either Party upon twelve (12) month written notice to the
other Party.
If SYMPHONIX decides not to renew the Agreement a fee will be payable by
SYMPHONIX to SIEMENS, such fee is one times the SIEMENS' prior twelve months
revenues with SYMPHONIX PRODUCTS in the TERRITORY.
Such fee will be payable 60 days after the effective date of the termination of
this AGREEMENT.
15. SYMPHONIX Change of Control
In the event of a Change in Control of SYMPHONIX (as defined herein), SYMPHONIX
shall have the right to terminate, with three (3) months written notice, this
AGREEMENT by paying SIEMENS the greater of (i) US$ 1,000,000 or 2 times SIEMENS'
prior twelve months revenues with SYMPHONIX PRODUCTS in the TERRITORY if this
AGREEMENT is terminated during the first or second year of the initial term of
this AGREEMENT, (ii) US$ 1,000,000 or 1.5 times SIEMENS' prior twelve months
revenues with SYMPHONIX PRODUCTS in the TERRITORY if this AGREEMENT is
terminated during the third year of the initial term or (iii) US$ 2,000,000 or 1
times SIEMENS' prior twelve months revenues with SYMPHONIX PRODUCTS in the
TERRITORY if this AGREEMENT is terminated during the fourth or fifth year of the
initial term. Upon a termination of this AGREEMENT for such reason SYMPHONIX
will have no further obligations to SIEMENS, and no additional payments will be
due as a result of such termination other than as set out in this paragraph.
Such fee will be payable 60 days after the effective date of the termination of
this AGREEMENT.
14
<PAGE>
A "Change in Control of SYMPHONIX " shall mean
(i) a merger, consolidation or other business combination or transaction to
which SYMPHONIX is a party if the stockholders of SYMPHONIX immediately
prior to the effective date of the merger, consolidation or other
business combination or transaction as a result of such share ownership
own less than 50 % of the voting power of the surviving corporation
following such merger, consolidation, or other business combination or
transaction,
(ii) an acquisition by any person of voting stock of SYMPHONIX representing
20 % or more of the total current voting power of SYMPHONIX,
(iii) a sale of all or substantially all the assets of SYMPHONIX or (iv) a
liquidation or dissolution of SYMPHONIX.
If the change in control results in an acquisition of SYMPHONIX by a
manufacturer of acoustic hearing aids, then this AGREEMENT may be cancelled by
SIEMENS at SIEMENS' option. Payments will be as set out above.
16. Arbitration
The Parties shall make a good faith effort to settle amicably any dispute or
difference arising out of or resulting from this AGREEMENT or ancillary
agreements regarding its performance. An attempt to arrive at a settlement shall
be deemed to have failed as soon as one of the Parties to this AGREEMENT so
notifies the other Party in writing.
If an attempt at settlement has failed, the dispute shall be resolved definitely
and exclusively by arbitration under the rules of arbitration of the
International Chamber of Commerce in Paris ("Rules") by three (3) arbitrators
appointed in accordance with the Rules.
The place of arbitration shall be Zurich, Switzerland. The procedural law of
that place shall apply where the Rules are silent. It is agreed that all
documentary submissions, presentations, and proceedings shall be in the English
language.
The arbitral award shall be substantiated in writing. The decision of the
arbitral tribunal shall be final and binding on the Parties, and judgement upon
the arbitral award may be entered in any court having jurisdiction thereof. The
arbitral tribunal shall assign the costs of arbitration.
15
<PAGE>
17. Applicable Law
The contractual relations between the Parties shall be governed by the
provisions of this AGREEMENT and all other agreements regarding its performance,
and otherwise in accordance with the substantive law in force in Switzerland.
The application of the United Nations Convention on contracts for the
International Sale of Goods of April 11, 1980, shall be excluded.
18. Miscellaneous
18.1. Supplemental agreements and amendments to this AGREEMENT must be made in
writing.
18.2. Neither Party may assign its rights or obligations under this AGREEMENT
without the prior written consent of the other Party, except to a
successor of all or substantially all of its business and/or properties.
IN WITNESS WHEREOF, the Parties have caused this AGREEMENT to be executed by
their duly authorized representatives on the dates as set forth below.
SYMPHONIX Devices, Inc. SIEMENS Audiologische Technik GmbH
Date: November 2, 1999 Date: November 2, 1999
Kirk Davis Hans Mehl
- ------------------------------ ------------------------------
President & Chief Executive Officer Managing Director
Annex 1: Current SYMPHONIX PRODUCTS
Annex 2: Territory
16
<PAGE>
ANNEX 1 - Current SYMPHONIX PRODUCTS
Vibrant P Soundbridge
Vibrant D Soundbridge
Related Programmers and Accessory Kits
17
<PAGE>
ANNEX 2 - TERRITORY
1. The countries currently comprising the European Union:
Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland,
Italy, Luxembourg, Netherlands, Portugal, Spain, Sweden, United Kingdom.
2. Additional countries in Western Europe:
Iceland, Liechtenstein, Norway, Switzerland.
18
EXHIBIT 7.3
November 22, 1999
CERTIFICATE
I, Dr. Peter Rieder, notary public with its official residence in 91054
Erlangen, Universitatsstr. 2 hereby confirm after inspection of the
authenticated extract of the Commercial Register of the County Council of
Charlottenburg dated 28.9.1999, HRB 12300, that
1. the Siemens Aktiengesellschaft with
registered place of business in Berlin and
Munich is entered in both Commercial
Registers and
2. Siemens Aktiengesellschaft is a company
organized under the law of the Federal
Republic of Germany and
3. Siemens Aktiengesellschaft is legally
represented by two Board Members or by two
fully authorized officers (Prokurist`s).
4. Mr. Dr. Wolfgang Muller-Huschke and Mr. Gotz
Steinhardt are entered as authorized officers
(Prokurist`s).
Erlangen, the 22nd of November 1999
/s/ Dr. Rieder
Notar/Notary Public
